<SEC-DOCUMENT>0001193125-24-107015.txt : 20240423
<SEC-HEADER>0001193125-24-107015.hdr.sgml : 20240423
<ACCEPTANCE-DATETIME>20240423161106
ACCESSION NUMBER:		0001193125-24-107015
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240409
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240423
DATE AS OF CHANGE:		20240423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMARIN PHARMACEUTICAL INC
		CENTRAL INDEX KEY:			0001048477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680397820
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26727
		FILM NUMBER:		24864923

	BUSINESS ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
		BUSINESS PHONE:		4155066700

	MAIL ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d797498d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bmrn="http://www.bmrn.com/20240409" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2024-04-09_to_2024-04-09">BIOMARIN PHARMACEUTICAL INC</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityAddressStateOrProvince" name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-04-09_to_2024-04-09">CA</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-274">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-04-09_to_2024-04-09">0001048477</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="bmrn-20240409.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-04-09_to_2024-04-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-09</xbrli:startDate> <xbrli:endDate>2024-04-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-285">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE&#160;SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-04-09_to_2024-04-09" format="ixt:datemonthdayyearen" id="ixv-286">April&#160;9, 2024</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">BIOMARIN PHARMACEUTICAL INC.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-04-09_to_2024-04-09" format="ixt-sec:stateprovnameen" id="ixv-287">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-288">000-26727</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-289">68-0397820</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-290">770 LINDARO STREET</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-291">SAN RAFAEL</ix:nonNumeric>, <span style=" -sec-ix-hidden:Hidden_dei_EntityAddressStateOrProvince">CALIFORNIA</span> &#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-292">94901</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-293">(415)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-294">505-6700</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-04-09_to_2024-04-09" format="ixt-sec:boolballotbox" id="ixv-295">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-04-09_to_2024-04-09" format="ixt-sec:boolballotbox" id="ixv-296">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-04-09_to_2024-04-09" format="ixt-sec:boolballotbox" id="ixv-297">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-04-09_to_2024-04-09" format="ixt-sec:boolballotbox" id="ixv-298">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-299">Common Stock, $0.001 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-300">BMRN</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-04-09_to_2024-04-09" format="ixt-sec:exchnameen" id="ixv-301">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-04-09_to_2024-04-09" format="ixt-sec:boolballotbox" id="ixv-302">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously reported, certain current and former officers of BioMarin Pharmaceutical Inc. (the &#8220;Company&#8221; or &#8220;BioMarin&#8221;) and certain current and former members of BioMarin&#8217;s board of directors have been named as defendants in consolidated stockholder derivative actions pending in the Court of Chancery of the State of Delaware (&#8220;Delaware Court of Chancery&#8221;), captioned <span style="font-style:italic">Wang v. Bienaim&#233;, et al.</span>, C.A. No. <span style="white-space:nowrap">2023-0058-NAC,</span> and in the United States District Court for the District of Delaware, captioned <span style="font-style:italic">Tsantes v. Bienaim&#233;, et al.</span>, C.A. No. <span style="white-space:nowrap">2023-0569-NAC.</span> The derivative actions in the Delaware Court of Chancery and the federal district court are referred to collectively as the &#8220;Derivative Actions.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;27, 2024, the parties in the Derivative Actions signed a Stipulation of Compromise and Settlement (the &#8220;Stipulation&#8221;) that will resolve the Derivative Actions. The proposed settlement of the Derivative Actions was filed in the Delaware Court of Chancery on March&#160;27, 2024, and is subject to final approval by the Delaware Court of Chancery. On April&#160;9, 2024, the Court granted with modifications the Parties&#8217; Proposed Scheduling Order, requiring the Company to file copies of the Stipulation and Exhibit C to the Stipulation as exhibits to a Current Report on Form <span style="white-space:nowrap">8-K</span> with the Securities and Exchange Commission within 14 days of the order. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to final approval of the settlement by the Delaware Court of Chancery, and in exchange for a release of all derivative claims and dismissal with prejudice of the Derivative Actions, the Company has agreed (i)&#160;to implement certain corporate governance reforms as set forth in Exhibit A to the Stipulation, and (ii)&#160;not to oppose plaintiffs&#8217; counsels request for a fee award not to exceed $1.25&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary description of the Stipulation is qualified in its entirety by the full text of the Stipulation, including all exhibits thereto, a copy of which is filed herewith as Exhibit 99.1. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Use of Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements made pursuant to the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i)&#160;the Stipulation resolving the Derivative Actions; (ii)&#160;the ability to secure approval of the proposed settlement from the Delaware Court of Chancery and to satisfy all conditions of the proposed settlement; and (iii)&#160;other statements that are not historical facts, constitute forward looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a)&#160;the Stipulation not having the expected impact, including resolving the Derivative Actions; (b)&#160;the proposed settlement requiring more activity or expense than expected; (c)&#160;the defendants&#8217; ability to overcome any objections or appeals regarding the proposed settlement; and (d)&#160;satisfactory resolution of any future litigation or other disagreements with others. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in BioMarin&#8217;s filings and periodic reports filed with the Securities and Exchange Commission under the heading &#8220;Risk Factors&#8221; and elsewhere in such filings and reports, including BioMarin&#8217;s annual report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2023 and future filings and reports by BioMarin. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, BioMarin disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.</p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d797498dex991.htm">Stipulation of Compromise and Settlement, dated March&#160;27, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">BIOMARIN PHARMACEUTICAL INC.,</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">a Delaware corporation</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: April&#160;23, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ G. Eric Davis</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">G. Eric Davis</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Executive Vice President, Chief Legal Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d797498dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EFiled: Mar 27 2024 12:01PM EDT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction ID 72616079</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Case No.
Multi-Case</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g797498g04g04.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ELAINE WANG, derivatively on</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">behalf of BIOMARIN</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PHARMACEUTICAL INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C.A. No. <FONT STYLE="white-space:nowrap">2023-0058-NAC</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:10.00em; font-size:10pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JEAN-JACQUES BIENAIM&Eacute;,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ELIZABETH MCKEE ANDERSON,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WILLARD DERE, ELAINE J.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HERON, ROBERT HOMBACH,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BRYAN LAWLIS, RICHARD A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MEIER, DAVID E. I. PYOTT,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DENNIS J. SLAMON, MICHAEL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GREY, MARK J. ALLES, MAYKIN</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HO, and HENRY J. FUCHS,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:10.00em; font-size:10pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BIOMARIN PHARMACEUTICAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Nominal Defendant.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Additional caption on next page</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BILL TSANTES, on behalf of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BIOMARIN PHARMACEUTICAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INC.,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C.A. No. <FONT STYLE="white-space:nowrap">2023-0569-NAC</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:10.00em; font-size:10pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JEAN-JACQUES BIENAIM&Eacute;,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ELIZABETH MCKEE ANDERSON,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WILLARD DERE, ELAINE J.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HERON, ROBERT HOMBACH,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BRYAN LAWLIS, RICHARD A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MEIER, DAVID E. I. PYOTT,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DENNIS J. SLAMON, MICHAEL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GREY, MARK J. ALLES, MAYKIN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HO, and HENRY J. FUCHS,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:10.00em; font-size:10pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BIOMARIN PHARMACEUTICAL INC.,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">a Delaware Corporation,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Nominal Defendant.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STIPULATION OF COMPROMISE AND SETTLEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Stipulation of Compromise and Settlement (the &#147;Stipulation&#148;) is made and entered into as of February&nbsp;8, 2024, between and
among: (a)&nbsp;plaintiffs Elaine Wang (&#147;Wang&#148;) and Bill Tsantes (&#147;Tsantes&#148; and collectively with Wang, &#147;Plaintiffs&#148;), on behalf of nominal defendant BioMarin Pharmaceuticals Inc. (&#147;BioMarin&#148; or the
&#147;Company&#148;), in the above-captioned stockholder derivative actions (the &#147;Derivative Actions&#148;), (b) individual defendants Jean-Jacques Bienaim&eacute; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(&#147;Bienaim&eacute;&#148;), Elizabeth McKee Anderson, Willard Dere, Elaine J. Heron, Robert Hombach,
Bryan Lawlis, Richard A. Meier, David E. I. Pyott, Dennis J. Slamon, Michael Grey, Mark J. Alles, Maykin Ho, and Henry J. Fuchs (&#147;Fuchs&#148;) (the &#147;Individual Defendants&#148;), and (c)&nbsp;nominal defendant BioMarin (together with the
Individual Defendants, the &#147;Defendants,&#148; and collectively with Plaintiffs, the &#147;Parties&#148; and each a &#147;Party&#148;). This Stipulation sets for the terms of and conditions of the settlement of the Derivative Actions (the
&#147;Settlement&#148;), subject to the approval of the Court of Chancery of the State of Delaware (the &#147;Court&#148;), and is intended to fully, finally, and forever compromise, discharge, resolve, release and settle the Released Claims (as
defined in paragraph 1.10 below). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SUMMARY OF THE PROCEEDINGS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Plaintiffs in the Derivative Actions allege that the Individual Defendants breached their fiduciary duties to BioMarin, and engaged in
other wrongdoing, by, <I>inter alia</I>, failing to adequately exercise oversight over the Company to prevent the issuance of materially false and misleading statements concerning the Company&#146;s application to the United States Food and Drug
Administration (the &#147;FDA&#148;) for approval of its &#147;Valrox&#148; gene therapy, and selling BioMarin stock at artificially inflated prices while in possession of material, <FONT STYLE="white-space:nowrap">non-public</FONT> Company
information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. On May&nbsp;4, 2021, Tsantes, a BioMarin stockholder, served BioMarin with a demand for
the inspection of books and records pursuant to 8 <I>Del. C. </I>&#167; 220 (&#147;&#167; 220&#148;) concerning potential wrongdoing in connection with various statements issued regarding Valrox. In response thereto, after BioMarin and Tsantes
negotiated the scope of a document production and entered into a confidentiality agreement, the Company produced 1,902 pages of internal, <FONT STYLE="white-space:nowrap">non-public</FONT> Company documents to Tsantes, which counsel for Tsantes
reviewed and analyzed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. On March&nbsp;14, 2022, Tsantes, through his counsel, served a <FONT STYLE="white-space:nowrap">pre-suit</FONT>
litigation demand (the &#147;Litigation Demand&#148;) on BioMarin&#146;s Board of Directors (the &#147;Board&#148;), which included certain allegations based on the confidential &#167; 220 materials, demanding that the Board cause the Company to
file an action against defendants Bienaim&eacute; and Fuchs for breach of fiduciary duty, contribution, and indemnification. The Litigation Demand also demanded that the Board commence an independent investigation in good faith into the events
regarding alleged breaches of fiduciary duties by other current and/or former officers and directors of the Company. The Litigation Demand further demanded that the Board cause BioMarin to enter into tolling agreements with each individual
implicated in the alleged wrongdoing to preserve the Company&#146;s claims during the pendency of the Board&#146;s investigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. On April&nbsp;25, 2022, Wang, a BioMarin stockholder, served BioMarin with a demand for
the inspection of books and records pursuant to &#167; 220. In response thereto, after BioMarin and Wang negotiated the scope of a document production and entered into a confidentiality agreement, the Company produced 1,248 pages of internal, <FONT
STYLE="white-space:nowrap">non-public</FONT> Company documents to Wang, which counsel for Wang reviewed and analyzed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. On June&nbsp;1,
2022, the Company responded to Tsantes&#146; Litigation Demand, stating that the Board determined it was in the best interests of the Company to defer consideration of the Litigation Demand during the pendency of a related federal securities class
action, <I>BioMarin Pharmaceutical Inc. Securities Litigation</I>, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:20-cv-06719-WHO</FONT></FONT></FONT> (N.D. Cal.) (the &#147;Securities
Class&nbsp;Action&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. On January&nbsp;19, 2023, Wang filed a Confidential Verified Stockholder Derivative Complaint in the action
<I>Wang v. Bienaim&eacute;, et al.</I>, C.A. No. <FONT STYLE="white-space:nowrap">2023-0058-NAC</FONT> (the &#147;<I>Wang </I>Action&#148;), putatively on behalf of the Company alleging, among other things, that the Individual Defendants breached
their fiduciary duties. Certain of the allegations in the <I>Wang </I>Action are based on the confidential &#167; 220 materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G. On
March&nbsp;1, 2023, Defendants filed a motion to dismiss the complaint in the <I>Wang </I>Action (the &#147;Motion to Dismiss&#148;) pursuant to Court of Chancery Rules 23.1 (&#147;Rule 23.1&#148;), 12(b)(1), and 12(b)(6). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">H. While the parties to the <I>Wang </I>Action were discussing a mutually agreeable briefing
schedule in connection with the Motion to Dismiss, the parties in the Securities Class&nbsp;Action reached a proposed settlement, and, on April&nbsp;28, 2023, moved for preliminary approval of that settlement. The settlement of the Securities
Class&nbsp;Action provides for a cash payment of $39,000,000.00 to the settlement class.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I. On June&nbsp;2, 2023, Tsantes filed a Confidential Verified Stockholder Derivative Complaint in the action <I>Tsantes v. Bienaim&eacute;,
et al.</I>, C.A. No. <FONT STYLE="white-space:nowrap">2023-0569-NAC</FONT> (the &#147;<I>Tsantes </I>Action&#148;), on behalf of the Company alleging, among other things, that the Individual Defendants breached their fiduciary duties. Certain of the
allegations in the <I>Tsantes </I>Action are based on the confidential &#167; 220 materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">J. Shortly thereafter, Plaintiffs agreed to
work cooperatively to attempt to negotiate a resolution of the claims asserted in the Derivative Actions and, in or about July 2023, commenced negotiations with Defendants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">K. The negotiations between the Parties continued for several months and, in October 2023, the Parties agreed to schedule a mediation with
Michelle Yoshida, Esq. (&#147;Ms.&nbsp;Yoshida&#148; or the &#147;Mediator&#148;) of Phillips ADR Enterprises (&#147;PADRE&#148;) to take place on November&nbsp;9, 2023. Ms.&nbsp;Yoshida served as the mediator in connection with the Securities
Class&nbsp;Action settlement. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Order and Final Judgment granting final approval to the settlement of the Securities Class&nbsp;Action were
entered on November&nbsp;14, 2023. Civ. Docket For Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:20-cv-06719-WHO,</FONT></FONT></FONT> ECF Nos. 155, 156. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">L. The Parties continued negotiations regarding the substantive terms of the Settlement and,
on November&nbsp;6, 2023, reached an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">agreement-in-principle</FONT></FONT> regarding those terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">M. Ms.&nbsp;Yoshida was provided with the substantive terms of the Settlement by the Parties and, on November&nbsp;9, 2023, conducted a full
day mediation session (the &#147;Mediation&#148;) with the Parties concerning the amount of attorneys&#146; fees and expenses to be paid to Plaintiffs&#146; Counsel (defined herein) in consideration of the substantial benefits achieved for the
Company and its current stockholders through the filing, litigation, and settlement of the Derivative Actions. By the conclusion of the Mediation, the Parties had reached an impasse and the Mediation session ended with no agreement reached by the
Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">N. On November&nbsp;10, 2023, Ms.&nbsp;Yoshida issued a double-blind mediator&#146;s recommendation to the Parties (the
&#147;Mediator&#146;s Proposal&#148;). The Mediator&#146;s Proposal recommended the payment of $1,250,000.00 in attorneys&#146; fees and expenses to Plaintiffs&#146; Counsel, subject to approval by the Court. The Parties accepted the Mediator&#146;s
Proposal on November&nbsp;10, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">O. The Parties agree that Plaintiffs commenced and pursued the Derivative Actions in good
faith, including the Litigation Demand and Plaintiffs&#146; <FONT STYLE="white-space:nowrap">pre-litigation</FONT> inspection demand efforts. Plaintiffs maintain that entry by Plaintiffs into this Stipulation is not an admission as to the lack of
any merit of any claims asserted by Plaintiffs in the Derivative Actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">JJ. Defendants have denied, and continue to deny, that they
committed any breach of duty, violated any law, or engaged in any wrongdoing, expressly maintain that they diligently and scrupulously complied with their fiduciary and other legal duties, to the extent such duties exist, and further believe that
the Derivative Actions are without merit. Defendants are entering into this Stipulation to eliminate the uncertainty, burden and expense of further protracted litigation. This Stipulation shall in no event be construed or deemed to be evidence of or
an admission or concession on the part of any of the Defendants, with respect to any claim or allegation of any fault or liability or wrongdoing or damage whatsoever, or any infirmity in the defenses that Defendants have, or could have, asserted in
the Derivative Actions. Defendants expressly deny that Plaintiffs have asserted any valid claims as to any of them, and expressly deny any and all allegations of fault, liability, wrongdoing or damages whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, IT IS HEREBY STIPULATED AND AGREED, BY AND AMONG THE PARTIES TO THIS STIPULATION, subject to the approval of the Court
pursuant to Rule 23.1, that the Derivative Actions shall be fully and finally compromised and settled, that the Released Claims shall be released by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Releasing Parties (as defined in paragraph 1.14 below) as against the Released Parties (as defined in
paragraph 1.12 below), and that the Derivative Actions shall be dismissed with prejudice, upon and subject to the following terms and conditions, and further subject to the approval of the Court: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DEFINITIONS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. </B>In addition
to the terms defined elsewhere in this Stipulation, the following terms have the meanings specified below: <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1
</B>&#147;Applicable BioMarin Stockholders&#148; means any and all individuals or entities who held of record, or beneficially owned, directly or indirectly, common stock of BioMarin as of the close of business on the date the Court enters the
Scheduling Order (as defined in paragraph 13 below), excluding the Individual Defendants, the officers and directors of BioMarin, members of their immediate families, and their legal representatives, heirs, successors, or assigns, and any entity in
which the Individual Defendants have or had a controlling interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2 </B>&#147;Corporate Governance Reforms&#148; means the
corporate governance reforms set forth in Exhibit A attached to this Stipulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3 </B>&#147;Defendants&#146; Released Claims&#148; means any and all claims, demands,
rights, liabilities, losses, obligations, duties, damages, costs, debts, expenses, interest, penalties, sanctions, fees, attorneys&#146; fees, actions, potential actions, causes of action, suits, judgments, defenses, counterclaims, offsets, decrees,
matters, issues and controversies of any kind, nature or description whatsoever, whether known or unknown, including Unknown Claims, that Plaintiffs asserted or could have asserted on behalf of nominal defendant BioMarin in the Derivative Actions or
in any other court, tribunal, forum or proceeding, whether based on state, federal, local, foreign, statutory, regulatory, common or other law or rule, and which are based upon, arise out of, or relate in any way to, or involve, directly or
indirectly, (a)&nbsp;the actions, inactions, deliberations, disclosures, discussions, decisions, votes, or any other conduct of any kind by any of the Released Defendant Parties (as defined below in paragraph 1.11), relating in any way to any facts,
matters, events, circumstances, claims, or allegations alleged or that could have been alleged in the Derivative Actions, or (b)&nbsp;the institution, commencement, prosecution, defense, mediation, or settlement of the Derivative Actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4 </B>&#147;Defendants&#146; Releasing Parties&#148; means Defendants and their respective agents, spouses, heirs, predecessors,
successors, transferors, transferees, personal representatives, representatives and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5 </B>&#147;Derivative Actions&#148;
means, collectively, the <I>Wang </I>Action and the <I>Tsantes </I>Action, as captioned above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6 </B>&#147;Final Approval&#148; means the later of (a)&nbsp;the expiration of the time
for the filing or noticing of an appeal or motion for reargument or rehearing from the Court&#146;s Order and Final Judgment (as defined below in paragraph 17) approving the Settlement; (b)&nbsp;the date of final affirmance of the Court&#146;s Order
and Final Judgment on any appeal or reargument or rehearing; or (c)&nbsp;the final dismissal of any appeal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7
</B>&#147;Plaintiffs&#146; Counsel&#148; means Rigrodsky Law, P.A., deLeeuw Law LLC, Shuman, Glenn&nbsp;&amp; Stecker, and Pomerantz LLP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8 </B>&#147;Plaintiffs&#146; Released Claims&#148; means all claims and causes of action of every nature and description, whether known
or unknown, whether arising under federal, state, common or foreign law, including Unknown Claims, that arise out of or relate in any way to Released Plaintiff Parties&#146; (as defined below in paragraph 1.13) institution, prosecution, or
settlement of the Derivative Actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9 </B>&#147;Plaintiffs&#146; Releasing Parties&#148; means Plaintiffs, BioMarin, and all
Applicable BioMarin Stockholders, whether acting directly, representatively, or derivatively on behalf of BioMarin, and their respective agents, spouses, heirs, predecessors, successors, transferors, transferees, personal representatives,
representatives and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10 </B>&#147;Released Claim(s)&#148; means Plaintiffs&#146; Released Claims and Defendants&#146;
Released Claims; <I>provided</I>, <I>however</I>, for the avoidance of doubt, that Released Claims shall not include any claims relating to the enforcement of this Stipulation or Settlement or any claims by BioMarin or the Individual Defendants for
insurance coverage or any claims by the Individual Defendants for indemnification or advancement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11 </B>&#147;Released Defendant Parties&#148; means all Defendants in the Derivative
Actions, and any and all of their and BioMarin&#146;s respective current or former agents, parents, controlling persons, general or limited partners, members, managers, managing members, direct or indirect equity holders, subsidiaries, affiliates,
employees, officers, directors, predecessors, successors, attorneys, heirs, assigns, insurers, reinsurers, consultants, and other representatives, servants and related persons, in their capacities as such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12 </B>&#147;Released Party&#148; or &#147;Released Parties&#148; means each and all of the Released Plaintiff Parties and the Released
Defendant Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13 </B>&#147;Released Plaintiff Parties&#148; means Plaintiffs and Plaintiffs&#146; Counsel and each of their
respective agents, assigns, and related persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14 </B>&#147;Releasing Parties&#148; means Plaintiffs&#146; Releasing Parties and
Defendants&#146; Releasing Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15 </B>&#147;Unknown Claims&#148; means any Released Claim which the Releasing Party does not
know or suspect to exist in his, her or its favor at the time of Final Approval of the Released Claims as against the Released Parties, including without limitation those which, if known, might have affected the decision to enter into or object to
the Settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RELEASES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. </B>Upon Final Approval of the Settlement, Plaintiffs&#146; Releasing Parties, by operation of the Settlement and to the fullest extent permitted by
law, shall completely, fully, finally and forever release, relinquish, settle and discharge each and all of the Released Defendant Parties from any and all of the Defendants&#146; Released Claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. </B>Upon Final Approval of the Settlement, Defendants&#146; Releasing Parties, by operation of the Settlement and to the fullest extent permitted by
law, shall completely, fully, finally and forever release, relinquish, settle and discharge each and all of the Released Plaintiff Parties from any and all of the Plaintiffs&#146; Released Claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. </B>The Settlement is intended to extinguish all of the Released Claims by the Releasing Parties as against the Released Parties and, consistent with
such intention, upon Final Approval of the Settlement, the Releasing Parties shall waive and relinquish, to the fullest extent permitted by law, the provisions, rights, and benefits of any state, federal, or foreign law or principle of common law,
which may have the effect of limiting the Released Claims. This shall include a waiver of any rights pursuant to California Civil Code &#167; 1542 (and equivalent, comparable, or analogous provisions of the laws of the United States or any state or
territory thereof, or of the common law), which provides: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THAT THE CREDITOR OR RELEASING PARTY DOES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FAVOR AT THE TIME OF EXECUTING THE RELEASE, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND THAT IF KNOWN BY HIM OR HER WOULD HAVE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MATERIALLY AFFECTED HIS OR HER SETTLEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITH THE DEBTOR OR THE RELEASED PARTY. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. </B>Plaintiffs acknowledge, and the Plaintiffs&#146; Releasing Parties shall be deemed by operation of the entry of the Order and Final Judgment upon
Final Approval of the Settlement to have acknowledged, that the foregoing waiver in paragraph 4 was expressly bargained for, is an integral term of the Settlement, and was relied upon by each and all of the Released Defendant Parties in entering
into the Settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. </B>Nothing herein shall in any way release, waive, impair, or restrict the rights of any Party to enforce the terms of this
Stipulation.<B> </B> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SETTLEMENT CONSIDERATION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. </B>The Parties agree that as a direct result of Plaintiffs&#146; investigation, initiation and litigation of the Derivative Actions, in consideration
for the full Settlement and release of the Released Claims, and upon Court approval of the Settlement, BioMarin will implement the Corporate Governance Reforms, of which Plaintiffs were a precipitating, substantial, and material cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. </B>In further consideration for the full Settlement and release of the Released Claims, BioMarin and the Individual Defendants also acknowledge that
Plaintiffs and the Derivative Actions were a precipitating, substantial, and material cause of BioMarin&#146;s adoption and implementation of the Corporate Governance Reforms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. </B>The Corporate Governance Reforms shall remain in effect for a period of at least four
(4)&nbsp;years from the date of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. </B>Defendants acknowledge that the Corporate Governance Reforms confer substantial benefits on the
Company and its current stockholders. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STAY OF PROCEEDINGS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. </B>Pending Final Approval of the Settlement by the Court, Plaintiffs agree to stay the Derivative Actions, and Plaintiffs and Plaintiffs&#146; Counsel
agree not to initiate any other proceedings related to the Derivative Actions other than those incident to the Settlement itself. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. </B>The Parties
will request that the Court order that, pending Final Approval of the Settlement, Plaintiffs and all Applicable BioMarin Stockholders are barred and enjoined from commencing, prosecuting, instigating or in any way participating in the commencement,
prosecution, or instigation of any action asserting any of the Released Claims, either directly, representatively, derivatively, or in any other capacity, against BioMarin, the Individual Defendants, or any of the Released Defendant Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SUBMISSION AND APPLICATION TO THE COURT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. </B>As soon as reasonably practicable after this Stipulation has been executed, the Parties shall jointly apply for a scheduling order (the
&#147;Scheduling Order&#148;), substantially in the form attached hereto as Exhibit B, establishing the procedure for the approval of notice to Applicable BioMarin Stockholders substantially in the form attached hereto as Exhibit C (the
&#147;Notice&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. </B>BioMarin shall undertake the primary responsibility for providing notice to Applicable BioMarin Stockholders, in accordance with the terms of the
Scheduling Order, and shall be solely responsible for paying the costs and expenses associated with providing the notice described in this paragraph. By no later than sixty (60)&nbsp;calendar days prior to the date the Court sets for the Settlement
Hearing (as defined below in paragraph 16), BioMarin shall mail the Notice, substantially in the form attached hereto as Exhibit C, to all Applicable BioMarin Stockholders who held of record at their respective addresses currently set forth in
BioMarin&#146;s stock records. In addition, the Company shall use reasonable efforts to give notice to all Applicable BioMarin Stockholders who were beneficial owners by: (a)&nbsp;filing copies of this Stipulation and the Notice as exhibits to a
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the United States Securities and Exchange Commission; (b)&nbsp;posting links to this Stipulation and the Notice on the Investor Relations portion of the Company&#146;s website
through the date of the Settlement Hearing; and (c)&nbsp;including in the Notice a statement that a copy of this Stipulation can be found on the Investor Relations portion of the Company&#146;s website, along with the website&#146;s address. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. </B>Counsel for BioMarin shall, at least ten (10)&nbsp;business days before the Settlement Hearing,
file with the Court an appropriate affidavit with respect to compliance with the requirements set forth in the foregoing paragraph. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ORDER AND FINAL JUDGMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.
</B>If the Settlement (including any modifications thereto made with the consent of the Parties as provided for herein) shall be approved by the Court following a hearing (the &#147;Settlement Hearing&#148;) as fair, reasonable, and adequate and in
the best interests of BioMarin, the Parties shall jointly request that the Court enter an order substantially in the form attached hereto as Exhibit D (the &#147;Order and Final Judgment&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. </B>The Order and Final Judgment shall, among other things, provide for full and complete dismissal of the Derivative Actions with prejudice, and the
Settlement and release of the Released Claims by the Releasing Parties as against the Released Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COOPERATION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. </B>The Parties and their respective counsel agree to cooperate fully with one another in seeking the Court&#146;s approval of the Settlement, and to
use their best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things reasonably necessary, proper, or advisable under applicable laws, regulations, and agreements to obtain the Court&#146;s approval of the
Settlement, consummate and make effective, as promptly as practicable, this Stipulation and the Settlement provided for hereunder (including, but not limited to, using their best efforts to resolve any objections raised to the Settlement) and the
dismissal of the Derivative Actions with prejudice without costs, fees or expenses to any Party (except as provided for herein). <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.
</B>Without further order of the Court, the Parties may agree to reasonable extensions of time not expressly set forth by the Court in order to carry out any provisions of this Stipulation.<B> </B> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONDITIONS OF SETTLEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.
</B>The Settlement is conditioned upon the fulfillment of each of the following: <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.1 </B>The entry by the Court of an Order
and Final Judgment in the form attached hereto as Exhibit D approving the proposed Settlement and dismissing the Derivative Actions with prejudice without the award of any damages, costs, fees or the grant of any further relief except for an award
of fees and expenses to Plaintiffs&#146; Counsel that the Court may make as contemplated herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>20.2 </B>Final Approval of the
Settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. </B>Each of BioMarin and the Individual Defendants shall have the right to withdraw from the
Settlement in the event that any claims related to the subject matter of the Derivative Actions are commenced or prosecuted against any of the Released Defendant Parties in any court prior to Final Approval of the Settlement and such claims are not
dismissed with prejudice or stayed in contemplation of dismissal following Final Approval of the Settlement. In the event such claims are commenced, the Parties agree to cooperate and use their reasonable best efforts to secure the dismissal thereof
or a stay in contemplation of dismissal following Final Approval of the Settlement. This Stipulation shall be null and void and of no force and effect if the Settlement does not obtain Final Approval for any reason. In such event, this Stipulation
shall not be deemed to prejudice in any way the respective positions of the Parties with respect to the Derivative Actions or to entitle any Party to the recovery of costs and expenses incurred in connection with the intended implementation of the
Settlement, including any costs related to providing notice to Applicable BioMarin Stockholders (as set forth in paragraph 14), to the extent such costs have already been incurred by BioMarin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. </B>In the event that the proposed Settlement is rendered null and void for any reason, the existence of or the provisions contained in this
Stipulation or any term sheet or other document relating to the terms of the proposed Settlement shall not be deemed to prejudice in any way the respective positions of the Parties with respect to the Derivative Actions; nor shall they be deemed a
presumption, a concession, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">an admission by the Parties of any fault, liability, wrongdoing or damages whatsoever as to any facts,
claims or defenses that have been or could have been alleged or asserted in the Derivative Actions, or any other action or proceeding or each thereof; nor shall they be interpreted, construed, deemed, invoked, offered, or received in evidence or
otherwise used by any person in the Derivative Actions, or in any other action or proceeding. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>WARRANTY AND <FONT
STYLE="white-space:nowrap">NON-ASSIGNMENT</FONT> OF CLAIMS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. </B>Plaintiffs and Plaintiffs&#146; Counsel represent and warrant that
Plaintiffs are current BioMarin stockholders and that none of Defendants&#146; Released Claims have been assigned, encumbered, or in any manner transferred in whole or in part, and that neither Plaintiffs nor Plaintiffs&#146; Counsel will attempt to
assign, encumber, or in any way transfer, in whole or in part, any of Defendants&#146; Released Claims. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ATTORNEYS&#146; FEES AND
REIMBURSEMENT OF EXPENSES FOR PLAINTIFFS&#146; COUNSEL </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24. </B>After negotiation of the principal terms of the Settlement, including the
Corporate Governance Reforms and the definition of Released Claims, the Parties participated in the <FONT STYLE="white-space:nowrap">full-day</FONT> Mediation session with the assistance of Ms.&nbsp;Yoshida of PADRE. By the conclusion of the
Mediation, the Parties were at an impasse and were unable to reach an agreement on the amount of attorneys&#146; fees and expenses for Plaintiffs&#146; Counsel in connection with the proposed Settlement of the Derivative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actions. After the Parties reached that impasse, Ms.&nbsp;Yoshida issued the double-blind Mediator&#146;s
Proposal to the Parties. Pursuant to the Mediator&#146;s Proposal, the Parties agreed that Plaintiffs&#146; Counsel shall receive an award of attorneys&#146; fees and expenses in the amount of $1,250,000.00 in the aggregate (the &#147;Fee
Award&#148;), subject to Court approval, and that Defendants will not oppose or object to the proposed Fee Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. </B>The Court may consider and
rule upon the fairness, reasonableness, and adequacy of the proposed Settlement independently of Plaintiffs&#146; Counsel&#146;s proposed Fee Award. The failure of the Court to approve the proposed Fee Award, in whole or in part, shall have no
effect on the validity of the Settlement or delay the enforceability of the Settlement, and final resolution by the Court of the proposed Fee Award shall not be a precondition to the dismissal with prejudice of the Derivative Actions. Any failure of
the Court to approve the proposed Fee Award, in whole or in part, shall not provide any of the Parties with the right to terminate the Settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.
</B>BioMarin&#146;s insurer(s) shall pay and/or cause to be paid any fee award entered by the Court as provided by the terms of such order within twenty (20)&nbsp;business days of entry of such order and Plaintiffs&#146; Counsel providing
BioMarin&#146;s counsel with the necessary information required for payment by check or a wire-transfer, including a signed <FONT STYLE="white-space:nowrap">W-9</FONT> and a tax ID number, with the Fee Award to be held in the escrow account of
Rigrodsky Law, P.A. No payments shall be made from the escrow account of Rigrodsky Law, P.A. until allocation of the Fee Award has been resolved pursuant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to paragraph 28 of this Stipulation. Any payment of any fee award provided herein shall be subject to
Plaintiffs&#146; Counsel&#146;s obligation to make refunds or repayments to BioMarin of any amounts paid, if the Settlement is terminated pursuant to the terms of this Stipulation or fails to become effective for any reason, or if, as a result of
any appeal of further proceedings on remand or successful collateral attack, the award of attorneys&#146; fees and/or expenses is reduced or reversed by final <FONT STYLE="white-space:nowrap">non-appealable</FONT> court order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27.</B> Plaintiffs may seek the Court&#146;s approval of reasonable service awards for each Plaintiff of up to $2,000.00, to be paid from the Fee Award,
and Defendants shall not oppose any such request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28.</B> Plaintiffs&#146; Counsel shall allocate the Fee Award among themselves. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STIPULATION NOT AN ADMISSION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>29.</B> Neither this Stipulation nor the Settlement, nor any act or omission taken in connection with this Stipulation or the Settlement, is intended or
shall be deemed to be a presumption, concession or admission by: (a)&nbsp;any of the Individual Defendants or any of the Released Defendant Parties as to the validity of any claims, causes of action or other issues that were or could have been
raised in the Derivative Actions or in any other litigation, or to be evidence of or constitute an admission of wrongdoing or liability by any of them, and each of them expressly denies any such wrongdoing or liability; or (b)&nbsp;Plaintiffs as to
the lack of merit of any claim or the validity of any defense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>30. </B>Any communications related to the Settlement, their contents or any of the negotiations,
statements, or proceedings in connection therewith shall not be offered or admitted in evidence or referred to, interpreted, construed, invoked, or otherwise used by any person for any purpose in the Derivative Actions or otherwise, except as may be
necessary to effectuate the Settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>31. </B>Paragraphs 21, 22, 29 and 30 shall remain in full force and effect in the event that the proposed
Settlement is terminated or fails to become effective for any reason. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NO WAIVER </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>32. </B>Any failure by any Party to insist upon the strict performance by any other Party of any of the provisions of the Settlement shall not be deemed a
waiver of any of the provisions of the Settlement, and such Party shall have the right thereafter to insist upon the strict performance of any and all of the provisions of the Settlement. All waivers must be in writing and signed by the Party
against whom the waiver is asserted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>33. </B>No waiver, express or implied, by any Party of any breach or default in the performance by any other
Party of its obligations pursuant to the Settlement shall be deemed or construed to be a waiver of any other breach, whether prior, subsequent or contemporaneous, under the terms of the Settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>BREACH </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>34.</B> The Parties agree that in the event of any breach of the Settlement, all of the Parties&#146; rights and remedies at law, equity, or otherwise, are
expressly reserved. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GOVERNING LAW </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>35.</B> This Stipulation and the Settlement contemplated by it shall be governed by, and construed in accordance with, the laws of the State of Delaware,
without regard to conflict of laws principles. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ENTIRE AGREEMENT; AMENDMENTS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>36.</B> This Stipulation constitutes the entire agreement among the Parties with respect to the subject matter hereof and may be modified or amended only
by a writing signed by the signatories hereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COUNTERPARTS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>37.</B> This Stipulation may be executed in multiple counterparts by any of the signatories hereto, including by facsimile, and as so executed shall
constitute one agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SUCCESSORS AND ASSIGNS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>38.</B> Except as expressly provided for herein, this Stipulation, and all rights and powers granted hereby, shall be binding upon and inure to the benefit
of the Parties and their respective agents, executors, heirs, successors, affiliates and assigns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COMPLIANCE WITH ETHICAL RULES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>39. </B>The Parties agree that throughout the course of the litigation, all Parties and their counsel complied with the provisions of Rule 11 of the Rules
of the Court of Chancery of the State of Delaware and that the Order and Final Judgment submitted to the Court will contain a statement to reflect this compliance. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>JURISDICTION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>40. </B>Any
action related to implementing and enforcing the Settlement shall be filed and litigated exclusively in the Court. Each Party (i)&nbsp;consents to personal jurisdiction in any such action brought in the Court, (ii)&nbsp;consents to service of
process by registered mail (with a copy to be delivered at the time of such mailing to counsel for each Party by facsimile or electronic mail) upon such Party and/or such Party&#146;s agent for purposes of such action, (iii)&nbsp;waives any
objection to venue in the Court and any claim that Delaware or the Court is an inconvenient forum for such action, and (iv)&nbsp;waives any right to demand a jury trial as to any such action.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AUTHORITY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>41. </B>The undersigned attorneys represent and warrant that they have the authority from their client(s) to enter into this Stipulation and bind their
client(s) thereto. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">DATED: March&nbsp;27, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">DELEEUW LAW LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">RIGRODSKY LAW, P.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Braford deLeeuw</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Seth D. Rigrodsky</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bradford deLeeuw (#3569)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Walnut Green
Road</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmington, DE 19807</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(302) <FONT
STYLE="white-space:nowrap">274-2180</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">brad@deleeuwlaw.com</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OF COUNSEL:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SHUMAN, GLENN&nbsp;&amp; STECKER</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kip B. Shuman</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Pine Street, Ste. 1250</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seth D. Rigrodsky (# 3147)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gina M. Serra
(#5387)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Herbert Mondros (#3308)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">300 Delaware Avenue, Suite
210</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmington, DE 19801</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(302)
<FONT STYLE="white-space:nowrap">295-5310</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">sdr@rl-legal.com</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">hwm@rl-legal.com</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">gma@rl-legal.com</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">San Francisco, CA 94111</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><I>Counsel for Plaintiff Elaine Wang</I></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">kip@shumanlawfirm.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(303) <FONT
STYLE="white-space:nowrap">861-3003</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">RICHARDS LAYTON &amp; FINGER, P.A.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">SHUMAN, GLENN&nbsp;&amp; STECKER</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Rusty E. Glenn</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt"><I>/s/ Ray J. DiCamillo</I></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">600 17th Street, Suite 2800 South</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Ray J. DiCamillo</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Denver, CO 80202</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-size:10pt">One Rodney Square</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">(303) <FONT STYLE="white-space:nowrap">861-3003</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-size:10pt">920 North King Street</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">rusty@shumanlawfirm.com</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-size:10pt">Wilmington, DE 19801</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">(302) <FONT STYLE="white-space:nowrap">651-7786</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">dicamillo@rlf.com</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SHUMAN, GLENN&nbsp;&amp; STECKER</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OF COUNSEL:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brett D. Stecker</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">326 W. Lancaster Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ardmore, PA 19003</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(303)
<FONT STYLE="white-space:nowrap">861-3003</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">brett@shumanlawfirm.com</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brett De Jarnette</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COOLEY LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3175 Hanover Street</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94304-1130</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(650)
<FONT STYLE="white-space:nowrap">849-7005</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">bdejarnette@cooley.com</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">POMERANTZ LLP</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gustavo F. Bruckner</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Samuel J. Adams</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankita
Sangwan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">600 Third Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10016</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(212) <FONT STYLE="white-space:nowrap">661-1100</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">gfbruckner@pomlaw.com</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">sjadams@pomlaw.com</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">asangwan@pomlaw.com</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Counsel for Plaintiff Bill Tsantes</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Counsel for Individual Defendants and</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Nominal Defendant</I> <I>BioMarin</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Pharmaceutical Inc.</I></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Multi-Case Filing Detail:</B> The document above has been filed and/or served into multiple cases, see
the details below including the case number and name. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction Details </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Court: </B>DE Court of Chancery Civil Action</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Document Type: </B>Stipulation for Compromise&nbsp;&amp; Settlement</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transaction ID: </B>72616079</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Document Title: </B>Stipulation of Compromise and Settlement</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Submitted Date</B><B></B><B>&nbsp;&amp; Time:</B> Mar 27 2024 12:01PM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Case Details </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Case Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Case Name</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">2023-0058-NAC</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elaine Wang vs. Jean-Jacques Bienaim&eacute;, et. al.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">2023-0569-NAC</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bill Tsantes v. Jean-Jacques Bienaim&eacute; et al</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>CORPORATE GOVERNANCE MEASURES TO BE IMPLEMENTED </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>AND MAINTAINED BY BIOMARIN </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within thirty (30)&nbsp;days of issuance of a final order approving the settlement of the Derivative Actions by the Delaware Court of Chancery
(the &#147;Court&#148;), the Board shall adopt resolutions to amend Board committee charters, or amend corporate governance documents, needed to ensure the adoption, implementation, and maintenance of the following Measures, which shall remain in
effect for no less than four (4)&nbsp;years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BioMarin also shall acknowledge that the Derivative Actions were a precipitating,
substantial and material factor in the adoption and implementation of these Measures by the Board and that the Measures confer substantial benefits upon BioMarin and its current stockholders. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ESTABLISHMENT OF A DISCLOSURE COMMITTEE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall formally establish a management-level Disclosure and Controls Committee (the &#147;Disclosure Committee&#148;). The
Disclosure Committee&#146;s functions and procedures should remain flexible to most effectively address changing circumstances. To implement the Committee&#146;s purposes and policies, the Disclosure Committee shall be charged with ensuring:
(i)&nbsp;the accuracy of earnings releases and material press releases; (ii)&nbsp;accurate filings with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;); (iii) the effectiveness of the Company&#146;s disclosure controls and
procedures. Nothing herein shall abrogate the disclosure oversight responsibilities of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mission of the Disclosure Committee
will include ensuring effective procedures and protocols are in place at the Company such that all the Company&#146;s SEC filings and material press releases are vetted for accuracy, integrity, and completeness, and for reviewing with management its
ongoing compliance with these protocols and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Disclosure Committee shall seek to ensure that material press releases and
SEC filings are accurate, not misleading, and timely with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s financial condition and business prospects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the developmental status of BioMarin&#146;s drug candidates, including but not limited to clinical trial results
and findings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s manufacturing and processing facilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the status of regulatory applications and proceedings; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s compliance with applicable laws and stock exchange requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of the Disclosure Committee shall be required prior to any earnings releases or SEC filings. The Disclosure Committee shall not grant any such
approval without first fully considering the Company&#146;s abilities to meet any applicable goals or targets and determining that any authorized corporate public statement is true and accurate. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Disclosure Committee shall hold regular meetings prior to the preparation and filing of
the Company&#146;s annual and quarterly reports with the SEC, and <I>ad hoc </I>meetings from time to time. Other personnel of the Company, or representatives of its outside advisors, may be invited to attend Disclosure Committee meetings as deemed
necessary or appropriate by the Disclosure Committee in performing its duties and responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Disclosure Committee shall
provide occasional updates to the Audit Committee as warranted under the circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of the Disclosure Committee
shall include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ensure that the Company&#146;s controls and procedures provide the information required to be disclosed by
the Company in the reports it files or submits under the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) and that other corporate information that the Company may disclose to the public is reported accurately and within the time
periods specified in the SEC&#146;s rules and regulations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Review the Company&#146;s SEC Form <FONT STYLE="white-space:nowrap">10-Qs,</FONT> Form <FONT
STYLE="white-space:nowrap">10-Ks</FONT> and material press releases. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Review (or delegate to an appropriate constituency the review of) the Company&#146;s other Exchange Act filings
(including SEC Form <FONT STYLE="white-space:nowrap">8-Ks</FONT> and Proxy Statements), registration statements, press releases containing financial information, information about material acquisitions or dispositions or other information material
to the Company&#146;s security holders, correspondence to stockholders, and presentations to analysts and investors, which includes analyst and investor conferences and scripts utilized during question and answer sessions of earnings conference
calls. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Review each Exchange Act report prior to its filing with the SEC to assess the quality of the disclosures
therein and whether the report is accurate and complete in all material respects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Review in advance the Company&#146;s quarterly earnings press releases and related materials (such as earnings
call scripts) to determine the adequacy and accuracy of the disclosures included therein. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SCIENCE AND TECHNOLOGY COMMITTEE ENHANCEMENTS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BioMarin shall amend the Charter for its Board-level Science and Technology Committee: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Purpose</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The charter
shall add to its purpose a bullet regarding evaluating the impacts of developments relating to preclinical studies and near-clinical phase programs on the Company&#146;s collaborations and drug development plans, including but not limited to
BioMarin&#146;s relationships with any collaborating entities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Composition</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Science Committee shall be comprised solely of Independent Directors (as defined in the existing charter) and persons who have no
financial or other material interest in any matter to be reviewed. At least two members of the Science Committee must be a scientist (Ph.D. level) or medical doctor, with relevant work and/or academic research experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Duties and Responsibilities</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Science Committee shall discharge its responsibilities and shall assess the information provided by the Company&#146;s management, in accordance with its independent business judgment. In the discharge of its responsibilities, the Science Committee
shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) From a scientific and technical perspective, review, evaluate, and advise the Board and management regarding the long-term
strategic goals and objectives and the quality and direction of the Company&#146;s R&amp;D programs, and regularly review the Company&#146;s R&amp;Dpipeline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Identify and discuss new and emerging trends in health care, pharmaceutical science, technology, manufacturing, and regulation to assist
the Company in making well-informed choices in the investment of its R&amp;D resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Recommend to the Board and management
emerging technologies for potentially building the Company&#146;s technological assets and capabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Advise the Board and
management on the scientific aspects of business development transactions submitted to the Board for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Assist management in
identifying world-class experts, including potential members for scientific advisory boards, to provide strategic scientific and clinical advice regarding the Company&#146;s programs. In coordination with the Company&#146;s management, engage with
the Company&#146;s scientific advisory boards and other advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) Serve as a sounding board for the Company&#146;s R&amp;D teams on
R&amp;D matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) Assist the Board with its oversight responsibility for enterprise risk management in areas affecting the
Company&#146;s R&amp;D activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) Monitor the Company&#146;s ongoing relationships with entities with which the Company has a
collaborating or other relationship, as well as federal and state regulators, including without limitation, the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) Review such
other topics as delegated to the Science Committee from time to time by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Science Committee shall ensure that the Audit Committee and the Board are promptly
made aware when any issues arising out of a clinical trial, including those pertaining to clinical trial data and protocols, are sufficiently material to trigger a disclosure obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Science Committee shall have access to all communications to the Company from the FDA, or from the FDA to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) BioMarin shall post the new Science Committee Charter on the Investor Relations portion of its website and shall include a link to this
charter in each Proxy Statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Procedures and Administration</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Science Committee shall meet from time to time as it deems necessary to perform its responsibilities, but in no event less than twice
annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Science Committee may form and delegate authority to one or more subcommittees, as it deems appropriate from time to
time under the circumstances (including a subcommittee consisting of a single member). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Science Committee shall report regularly,
but in no event less than twice annually, to the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Science Committee shall, from time to time as it deems appropriate,
review and reassess the adequacy of its Charter and recommend any proposed changes to the Board for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Science Committee
shall have the authority to engage such external advisors as it deems necessary or appropriate to carry out its responsibilities. The Science Committee is empowered, without further action by the Board, to cause the Company to pay the compensation
of such advisors as established by the Science Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Science Committee may from time to time request any officer(s),
employee(s) or advisor(s) of the Company to meet with the Science Committee or any advisor(s) engaged by the Science Committee. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PUBLIC DATA DISCLOSURES TO STOCKHOLDERS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If management and/or the Board chooses to publicly release interim product candidate results, the Company will do so in a manner that is not
false or misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At least a subset of the Disclosure Committee shall review any disclosure releasing new clinical trial data before
it disseminated to investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>IMPROVEMENTS TO THE AUDIT COMMITTEE</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioMarin shall adopt a resolution to amend its Audit Committee Charter. The amended Audit Committee Charter shall be posted on the Investor Relations section
of the Company&#146;s website. The Audit Committee Charter shall be amended as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Audit Committee shall plan to meet at
least six (6)&nbsp;times annually and in separate executive sessions with the Company&#146;s management, independent auditor, and CCO in carrying out its duties. The CFO will not be present at such meetings; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Audit Committee shall, in conjunction with BioMarin&#146;s independent outside auditor, annually review staffing of the Company&#146;s
internal audit function to ensure that necessary staffing levels of the internal audit function are fulfilled and maintained; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The
Audit Committee shall meet with the Disclosure Committee, or its designee, at least four times annually to discuss the Company&#146;s R&amp;D, production, and/or marketing goals as it relates to material press releases, SEC Form <FONT
STYLE="white-space:nowrap">10-Qs,</FONT> and Form <FONT STYLE="white-space:nowrap">10-Ks</FONT> to align on processes and procedures to facilitate accurate public disclosures. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LIMITED DIRECTOR AND COMMITTEE ENGAGEMENTS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioMarin shall limit director and committee engagements outside the Company to help ensure that each director fulfills his or her fiduciary oversight duties by
devoting sufficient attention to BioMarin&#146;s business and operations. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXPANSION OF THE DUTIES AND RESPONSIBILITIES OF THE GENERAL COUNSEL</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The duties and responsibilities of the Company&#146;s General Counsel shall be expanded to include the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Acting as liaison between management the Board, and the Audit Committee. In working closely with the CCO, the General Counsel shall:
(i)&nbsp;be primarily responsible for identifying and initiating investigations into material misconduct and noncompliance with applicable laws and regulations; (ii)&nbsp;if the General Counsel determines that there has been <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with applicable laws and regulations, report those issues to the Disclosure Committee and the Audit Committee, within three days of identification of these issues; and (iii)&nbsp;make recommendations
for further evaluation and/or remedial action within deadlines agreed to by the Disclosure and Audit Committees; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As part of the
Disclosure Committee, review BioMarin&#146;s draft quarterly and annual reports, filed with the SEC on Forms <FONT STYLE="white-space:nowrap">10-K</FONT> and <FONT STYLE="white-space:nowrap">10-Q,</FONT> and related materials prior to their
publication to ensure (i)&nbsp;the accuracy, completeness, and timeliness of disclosures relating to compliance with applicable laws and regulations; and (ii)&nbsp;accurate reporting of any material issues that may&#8195;merit disclosure to other
BioMarin constituencies; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) As part of the disclosure committee, reviewing BioMarin&#146;s press releases and related materials prior to
their publication to ensure the accuracy, completeness, and timeliness of disclosures relating to BioMarin&#146;s compliance with applicable laws and regulations, and reporting any material issues that may merit disclosure to other BioMarin
constituencies; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Working with the Audit Committee as a part of the Disclosure Committee&#146;s
subcommittee to evaluate the adequacy of BioMarin&#146;s internal controls over compliance and develop proposals for improving these controls. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTERNAL CONTROLS AND COMPLIANCE FUNCTIONS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) By no later than December&nbsp;31, 2024. the Board shall work with an independent consultant to strengthen its internal audit and control
functions, including, but not limited to, the accuracy of public disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The consultant shall prepare a written report with
recommended changes, if any, to the Audit Committee. This consultant shall meet with the Board and a member of senior management to present the written report in advance of BioMarin&#146;s finalization of its annual Form <FONT
STYLE="white-space:nowrap">10-K</FONT> report for the year end December&nbsp;31, 2024. The Board shall consider implementation of each recommendation contained in the report, and such consideration shall be recorded in the meeting minutes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BioMarin&#146;s CFO shall not have been employed by any of BioMarin&#146;s outside auditor firms during the prior two (2)&nbsp;years or, if
involved in the auditor firm&#146;s audit of BioMarin, during the prior five (5)&nbsp;years. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INSIDER TRADING POLICY AND CONTROLS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent not already required under the Global Code of Conduct and Business Ethics, the Company&#146;s Insider Trading Policy shall be
amended as follows, and shall be posted, as amended, on the Company website. To the extent insiders elect to enter into <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans (&#147;Trading Plans&#148;), such plans should be structured
pursuant to the following rules: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Trading Plans shall prohibit the commencement of trading until ninety days (90)&nbsp;following a
Trading Plan&#146;s adoption; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The adoption of a Trading Plan, and the aggregate number of shares involved, shall be publicly
disclosed for Section&nbsp;16 officers; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Trading Plans shall only be adopted during &#147;open window&#148; periods; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) All Trading Plans shall be approved by the Company&#146;s General Counsel or designee. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DIRECTOR EDUCATION</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioMarin shall require that every three years, each member of the Board shall receive director training and that training may be conducted either at an outside
entity or internally by the Company&#146;s General Counsel or outside counsel. Any such programs or training may concern, for example, compliance with laws and regulations, disclosures to stockholders, and fiduciary duties in the context of a
regulated public company, including compliance with GAAP, the Sarbanes- Oxley Act, corporate governance, assessment of risk, compliance auditing, and reporting requirements for publicly-traded corporations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new Board members shall receive such training within six (6)&nbsp;months of election or
appointment to the Board. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EMPLOYEE TRAINING</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall provide all new hires and appropriate employee populations with training on expectations with respect to integrity and
compliance and the Code of Conduct. The Company shall require the appropriate employee populations to attest on an annual basis that they have read, understand, and will comply with the Code of Conduct. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHISTLEBLOWER POLICY</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall adopt and implement a written policy (the &#147;Whistleblower Policy&#148;) to protect employees, contractors, vendors and
other individuals from retaliation for reporting misconduct, <FONT STYLE="white-space:nowrap">non-compliance</FONT> with applicable laws and regulations or violations of the Company&#146;s Corporate Governance Principles, Global Code of Conduct and
Business Ethics, Corporate Compliance and Ethics Program, and Environmental, Social and Governance (ESG) Practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Whistleblower
Policy will adequately notify employees of the following: (i)&nbsp;complaints may be directed to an employee&#146;s manager, any member of Human Resources, that employee&#146;s designated officer, or via a whistleblower phone number (the
&#147;Reporting Hotline&#148;); (ii) reports made through the Reporting Hotline made be made anonymously (unless prohibited by local law); (iii) information gathered during investigations into reports will be kept confidential to the extent
possible; and (iv)&nbsp;BioMarin strictly prohibits retaliation against any individual who raises complaints in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
shall post information regarding the Reporting Hotline phone number on the Company website and make clear that it is available to assist on matters pertaining to a potential violation of the Code of Conduct. The Reporting Hotline shall be
confidential, and reports made to the Reporting Hotline relating to accounting, auditing, or embezzlement matters shall be directed to the Chairperson of the Audit Committee. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICE COSTS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defendants must pay for and administer notice of any settlement in a form and manner mutually acceptable to the parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Multi-Case Filing Detail:</B> The document above has been filed and/or served into multiple cases, see
the details below including the case number and name. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Transaction Details</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Court:</B> DE Court of Chancery Civil Action</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Document Type:</B> Exhibits</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transaction ID:</B> 72616079</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Document Title:</B> Exhibit A to Stipulation of Compromise and Settlement</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Submitted Date&nbsp;&amp; Time:</B> Mar 27 2024 12:01PM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Case Details</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Case Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Case Name</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">2023-0058-NAC</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elaine Wang vs. Jean-Jacques Bienaim&eacute;, et. al.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">2023-0569-NAC</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bill Tsantes v. Jean-Jacques Bienaim&eacute; et al</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EFiled: Mar 27 2024 12:01PM EDT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction ID 72616079</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Case No.
Multi-Case</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g797498g41g41.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ELAINE WANG, derivatively on</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">behalf of BIOMARIN</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PHARMACEUTICAL INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C.A. No. <FONT STYLE="white-space:nowrap">2023-0058-NAC</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:10.00em; font-size:10pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JEAN-JACQUES BIENAIM&Eacute;,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ELIZABETH MCKEE ANDERSON,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WILLARD DERE, ELAINE J.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HERON, ROBERT HOMBACH,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BRYAN LAWLIS, RICHARD A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MEIER, DAVID E. I. PYOTT,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DENNIS J. SLAMON, MICHAEL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GREY, MARK J. ALLES, MAYKIN</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HO, and HENRY J. FUCHS,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:10.00em; font-size:10pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BIOMARIN PHARMACEUTICAL INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Nominal Defendant.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Additional caption on next page</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BILL TSANTES, on behalf of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BIOMARIN PHARMACEUTICAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INC.,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">C.A. No. <FONT STYLE="white-space:nowrap">2023-0569-NAC</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:10.00em; font-size:10pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JEAN-JACQUES BIENAIM&Eacute;,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ELIZABETH MCKEE ANDERSON,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WILLARD DERE, ELAINE J.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HERON, ROBERT HOMBACH,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BRYAN LAWLIS, RICHARD A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MEIER, DAVID E. I. PYOTT,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DENNIS J. SLAMON, MICHAEL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GREY, MARK J. ALLES, MAYKIN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HO, and HENRY J. FUCHS,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:10.00em; font-size:10pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BIOMARIN PHARMACEUTICAL INC., a Delaware Corporation,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:8.00em; font-size:10pt; font-family:Times New Roman">Nominal Defendant.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF ACTIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: ALL PERSONS OR ENTITIES WHO HELD SHARES OF COMMON STOCK OF BIOMARIN PHARMACEUTICAL INC., EITHER OF RECORD OR BENEFICIALLY, AS OF
<U>April</U><U></U><U>&nbsp;9</U>, 2024 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>IF YOU HOLD COMMON STOCK OF BIOMARIN PHARAMCEUTICAL INC. FOR THE BENEFIT OF ANOTHER, PLEASE
PROMPTLY TRANSMIT THIS DOCUMENT TO SUCH BENEFICIAL OWNER.</B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this Notice is to inform you of (i)&nbsp;the pendency of the above- captioned
actions (the &#147;Derivative Actions&#148;), which were brought in the Court of Chancery of the State of Delaware (the &#147;Court&#148;) by stockholders of BioMarin Pharmaceutical Inc. (&#147;BioMarin&#148; or the &#147;Company&#148;), asserting
claims derivatively on behalf of the Company; (ii)&nbsp;the proposed settlement of the Derivative Actions (the &#147;Settlement&#148;), subject to Court approval and subject to other conditions of the Settlement being satisfied, as provided for in a
Stipulation of Compromise and Settlement dated March&nbsp;27, 2024 (the &#147;Stipulation&#148;), which was filed with the Court and is publicly available for review; and (iii)&nbsp;your right to participate in a hearing to be held on July&nbsp;23,
2024, at <U>11</U>:<U>00</U> a.m., before the Court at the Court of Chancery of the State of Delaware, Leonard L. Williams Justice Center, 500 North King Street, Wilmington, DE 19801(the &#147;Settlement Hearing&#148;). The purposes of the
Settlement Hearing are to determine whether the Court should: (i)&nbsp;approve the proposed Settlement as fair, reasonable and adequate; (ii)&nbsp;dismiss the Derivative Actions with prejudice; (iii)&nbsp;enter an Order and Final Judgment approving
the Settlement; (iv)&nbsp;approve a petition for an award of attorneys&#146; fees and expenses to Plaintiffs&#146; Counsel in the Derivative Actions (the &#147;Fee Award&#148;); (v) approve an application for fee for the reasonable services of each
Plaintiff to be paid from the Fee Award (the &#147;Service Award&#148;); and (vi)&nbsp;hear and determine any objections to the Settlement, the Fee Award or the Service Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE RELATES TO A PROPOSED SETTLEMENT OF THE LITIGATION REFERRED TO IN THE
CAPTIONS AND CONTAINS IMPORTANT INFORMATION REGARDING YOUR RIGHTS. IF THE COURT APPROVES THE PROPOSED SETTLEMENT, YOU WILL BE FOREVER BARRED FROM CONTESTING THE FAIRNESS, REASONABLENESS OR ADEQUACY OF THE PROPOSED SETTLEMENT, AND FROM PURSUING THE
RELEASED CLAIMS (AS DEFINED BELOW).</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stipulation was entered into as of March&nbsp;27, 2024 by and among (i)&nbsp;Elaine Wang
(&#147;Wang&#148;), the plaintiff in the above-captioned action <I>Wang v. Bienaim&eacute;, et al.</I>, C.A. No. <FONT STYLE="white-space:nowrap">2023-0058-NAC</FONT> (Del. Ch.) (the &#147;<I>Wang</I> Action&#148;); (ii) Bill Tsantes
(&#147;Tsantes&#148; and together with Wang, &#147;Plaintiffs&#148;), the plaintiff in the above-captioned action <I>Tsantes v. Bienaim&eacute;, et al.</I>, C.A. No. <FONT STYLE="white-space:nowrap">2023-0569-NAC</FONT> (Del. Ch.); defendants
Jean-Jacques Bienaim&eacute;, Elizabeth McKee Anderson, Willard Dere, Elaine J. Heron, Robert Hombach, Bryan Lawlis, Richard A. Meier, David E. I. Pyott, Dennis J. Slamon, Michael Grey, Mark J. Alles, Maykin Ho, and Henry J. Fuchs (the
&#147;Individual Defendants&#148;); and (iv)&nbsp;Nominal Defendant BioMarin (and together with the Individual Defendants, &#147;Defendants&#148;). Plaintiffs and Defendants are collectively referred to herein as the &#147;Parties.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Notice describes the rights you may have in the Derivative Actions and, pursuant to the
Stipulation, what steps you may take, but are not required to take, in relation to the Settlement. If the Court approves the Settlement, the Parties will ask the Court at the Settlement Hearing to enter an Order and Final Judgment dismissing the
Derivative Actions with prejudice in accordance with the terms of the Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These Derivative Actions were brought as stockholder
derivative actions on behalf of the Company. The benefits of the Settlement will go to the Company. Other than any award by the Court of fees and expenses to Plaintiffs&#146; Counsel, or any fee for the reasonable services of each Plaintiff to be
paid from the attorneys&#146; fees awarded to Plaintiffs&#146; Counsel, no monetary payments under the Settlement will be made. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WHAT IS
THE PURPOSE OF THIS NOTICE? </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The purpose of this Notice is to explain the Derivative Actions, the terms of the proposed Settlement, and
how the Settlement affects the legal rights of the Company&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. In a derivative action, one or more people and/or
entities who are current stockholders of a corporation sue on behalf of and for the benefit of the corporation, seeking to enforce the corporation&#146;s legal rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. As described more fully in paragraphs <FONT STYLE="white-space:nowrap">35-36</FONT> below, current stockholders have the right to object to
the proposed Settlement, the Fee Award or the Service Award. They have the right to appear and be heard at the Settlement Hearing, which will be held before The Honorable Nathan A. Cook on July&nbsp;23, , 2024, at 11:00 a.m., Court of Chancery of
the State of Delaware, Leonard L. Williams Justice Center, 500 North King Street, Wilmington, DE 19801 or as may be undertaken via a remote proceeding such as Zoom or by telephone. At the Settlement Hearing, the Court will: (a)&nbsp;determine
whether the proposed Settlement should be approved as fair, reasonable and adequate; (b)&nbsp;determine whether the Court should finally approve the Stipulation and enter the Order and Final Judgment as provided in the Stipulation and dismiss the
Derivative Actions with prejudice, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereby extinguishing and releasing the Released Claims; (c)&nbsp;determine whether and in what amount an award of attorneys&#146; fees (including expenses) should be paid to Plaintiffs&#146;
Counsel in the Fee Award; (d)&nbsp;determine whether and in what amount a Service Fee should be paid to Plaintiffs from the Fee Award; (e)&nbsp;hear and determine any objections to the Settlement, the Fee Award, the Service Award; and (e)&nbsp;rule
on any other matters the Court may deem appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Court has reserved the right to adjourn or continue the Settlement Hearing,
including consideration of the application by Plaintiffs&#146; Counsel for the Fee Award and/or Plaintiffs&#146; application for the Service Award to be paid from the Fee Award, without further notice to you other than by announcement at the
Settlement Hearing or any adjournment thereof, or notation on the docket in the Derivative Actions. The Court has further reserved the right to approve the Settlement, at or after the Settlement Hearing, with such modifications as may be consented
to by the Parties and without further notice of any kind. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WHAT IS THIS CASE ABOUT? WHAT HAS HAPPENED SO FAR? </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>THE FOLLOWING RECITATION DOES NOT CONSTITUTE FINDINGS OF THE COURT AND SHOULD NOT BE UNDERSTOOD AS AN EXPRESSION OF ANY OPINION OF THE
COURT AS TO THE MERITS OF ANY CLAIMS OR DEFENSES BY ANY OF THE PARTIES. IT IS BASED ON STATEMENTS OF THE PARTIES AND IS SENT FOR THE SOLE PURPOSE OF INFORMING YOU OF THE EXISTENCE OF THE DERIVATIVE ACTIONS AND OF A HEARING ON A PROPOSED SETTLEMENT
SO THAT YOU MAY MAKE APPROPRIATE DECISIONS AS TO STEPS YOU MAY, OR MAY NOT, WISH TO TAKE IN RELATION TO THIS LITIGATION.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. BioMarin,
a publicly traded Delaware corporation with its principal executive offices located in San Rafael, California, is a pharmaceutical company that developed Valrox, a gene therapy treatment for hemophilia A, a hereditary disease caused by the lack of a
blood clotting protein called &#147;Factor VII.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Plaintiffs allege that between March&nbsp;3, 2020 and August&nbsp;18, 2020 (the
&#147;Relevant Period&#148;), Defendants&cedil; among other things, breached their fiduciary duties by issuing, and/or permitting the issuance of, materially false and misleading statements regarding the status of the U.S. Food and Drug
Administration&#146;s (the &#147;FDA&#148;) approval process for Valrox. Plaintiffs allege that the Individual Defendants failed to disclose that the FDA had informed the Company in June 2020 that approval of Valrox by August 2020, the deadline
under the Prescription Drug User Fee Act, was virtually impossible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. On August&nbsp;19, 2020, the Company announced that the FDA would
not approve Valrox at that time. On this news, BioMarin stock dropped by $41.82 per share, or 35%, to close at $76.72 per share on August&nbsp;19, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. On May&nbsp;4, 2021, Tsantes, a BioMarin stockholder, served BioMarin with a demand for the inspection of books and records pursuant to 8
Del. C. &#167; 220 (&#147;&#167; 220&#148;) concerning potential wrongdoing in connection with various statements issued regarding Valrox. In response thereto, after BioMarin and Tsantes negotiated the scope of a document production and entered into
a confidentiality agreement, the Company produced 1,902 pages of internal, <FONT STYLE="white-space:nowrap">non-public</FONT> Company documents to Tsantes, which counsel for Tsantes reviewed and analyzed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. On March&nbsp;14, 2022, Tsantes, through his counsel, served a <FONT STYLE="white-space:nowrap">pre-suit</FONT> litigation demand (the
&#147;Litigation Demand&#148;) on BioMarin&#146;s Board of Directors (the &#147;Board&#148;), which included certain allegations based on the confidential &#167; 220 materials, demanding that the Board cause the Company to file an action against
defendants Bienaim&eacute; and Fuchs for breach of fiduciary duty, contribution, and indemnification. The Litigation Demand also demanded that the Board commence an independent investigation in good faith into the events regarding alleged breaches
of fiduciary duties by other current and/or former officers and directors of the Company. The Litigation Demand further demanded that the Board cause BioMarin to enter into tolling agreements with each individual implicated in the alleged wrongdoing
to preserve the Company&#146;s claims during the pendency of the Board&#146;s investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. On April&nbsp;25, 2022, Wang, a BioMarin
stockholder, served BioMarin with a demand for the inspection of books and records pursuant to &#167; 220. In response thereto, after BioMarin and Wang negotiated the scope of a document production and entered into a confidentiality agreement, the
Company produced 1,248 pages of internal, <FONT STYLE="white-space:nowrap">non-public</FONT> Company documents to Wang, which counsel for Wang reviewed and analyzed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. On June&nbsp;1, 2022, the Company responded to Tsantes&#146; Litigation Demand, stating
that the Board determined it was in the best interests of the Company to defer consideration of the Litigation Demand during the pendency of a related federal securities class action, <I>BioMarin Pharmaceutical Inc. Securities Litigation</I>, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:20-cv-06719-WHO</FONT></FONT></FONT> (N.D. Cal.) (the &#147;Securities Class&nbsp;Action&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. On January&nbsp;19, 2023, Wang filed a Confidential Verified Stockholder Derivative Complaint in the action <I>Wang v.
Bienaim&eacute;</I>, et al., C.A. No.&nbsp;2023-0058- NAC (the &#147;Wang Action&#148;), on behalf of the Company alleging, among other things, that the Individual Defendants breached their fiduciary duties. Certain of the allegations in the Wang
Action are based on the confidential &#167; 220 materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. On March&nbsp;1, 2023, Defendants filed a motion to dismiss the complaint
in the <I>Wang</I> Action (the &#147;Motion to Dismiss&#148;) pursuant to Court of Chancery Rules 23.1 (&#147;Rule 23.1&#148;), 12(b)(1), and 12(b)(6). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. While the parties to the <I>Wang</I> Action were discussing a mutually agreeable briefing schedule in connection with the Motion to
Dismiss, the parties in the Securities Class&nbsp;Action reached a proposed settlement, and, on April&nbsp;28, 2023, moved for preliminary approval of that settlement. The settlement of the Securities Class&nbsp;Action provides for a cash payment of
$39,000,000.00 to the class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. A hearing on the motion for final approval of the settlement of the Securities Class&nbsp;Action was
conducted on November&nbsp;8, 2023. That same day, the United States District Court for the Northern District of California entered a Minute Order that states &#147;[t]he Court finds the settlement to be fair, adequate, and reasonable and
anticipates granting final approval.&#148; <I>See</I> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:20-cv-06719-WHO,</FONT></FONT></FONT> ECF No, 153. The order granting final approval of the
Securities Class&nbsp;Action settlement was entered on November&nbsp;14, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. On June&nbsp;2, 2023, Tsantes filed a Confidential
Verified Stockholder Derivative Complaint in the action <I>Tsantes v. Bienaim&eacute;, et al.</I>, C.A. No.&nbsp;2023-0569- NAC (the &#147;<I>Tsantes</I> Action&#148;), on behalf of the Company alleging, among other things, that the Individual
Defendants breached their fiduciary duties. Certain of the allegations in the <I>Tsantes</I> Action are based on the confidential &#167; 220 materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. Shortly thereafter, Plaintiffs agreed to work cooperatively to attempt to negotiate a resolution of the claims asserted in the Derivative
Actions and, in or about July 2023, commenced negotiations with Defendants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. The negotiations between the Parties continued for
several months and, in October 2023, the Parties agreed to schedule a mediation with Michelle Yoshida, Esq. (&#147;Ms.&nbsp;Yoshida&#148; or the &#147;Mediator&#148;) of Phillips ADR Enterprises (&#147;PADRE&#148;) to take place on November&nbsp;9,
2023. Ms.&nbsp;Yoshida served as the mediator in connection with the Securities Class&nbsp;Action settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. The Parties continued negotiations regarding the substantive terms of the Settlement
and, on November&nbsp;6, 2023, reached an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">agreement-in-principle</FONT></FONT> regarding those terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. Ms.&nbsp;Yoshida was provided with the substantive terms of the Settlement by the Parties and, on November&nbsp;9, 2023, conducted a full
day mediation session (the &#147;Mediation&#148;) with the Parties concerning the amount of attorneys&#146; fees and expenses to be paid to Plaintiffs&#146; Counsel (defined herein) in consideration of the substantial benefits achieved for the
Company and its current stockholders through the filing, litigation, and settlement of the Derivative Actions. By the conclusion of the Mediation, the Parties had reached an impasse and the Mediation session ended with no agreement reached by the
Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. On November&nbsp;10, 2023, Ms.&nbsp;Yoshida issued a double-blind mediator&#146;s recommendation to the Parties (the
&#147;Mediator&#146;s Proposal&#148;). The Mediator&#146;s Proposal recommended the payment of $1,250,000.00 in attorneys&#146; fees and expenses to Plaintiffs&#146; Counsel, subject to approval by the Court. The Parties accepted the Mediator&#146;s
Proposal on November&nbsp;10, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. The Parties executed the Stipulation on March&nbsp;27, 2024. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WHAT ARE THE TERMS OF THE SETTLEMENT? </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. Set forth below is a summary of the principal terms of the proposed Settlement, as agreed to by the Parties, subject to the approval of
the Court. The following statements are a summary, and reference is made to the Stipulation, which is publicly available as indicated in paragraph 37 below, for a full and complete statement of the terms of the Settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. In consideration for the full settlement and release of the Released Claims (as defined below), and subject to the terms and conditions
set forth in the Stipulation, within thirty (30)&nbsp;days after entry of Judgment, BioMarin&#146;s Board shall adopt resolutions and amend its Bylaws, committee Charters, and other applicable corporate policies to implement the following reforms
(the &#147;Reforms&#148;) set forth below, which shall remain in effect for no less than four (4)&nbsp;years (the &#147;Term&#148;): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>The Disclosure and Controls Committee </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will establish a management-level Disclosure and Controls Committee (the &#147;Disclosure
Committee&#148;). The Disclosure Committee shall be charged with ensuring: (i)&nbsp;the accuracy of earnings releases and material press releases; (ii)&nbsp;accurate filings with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;);
(iii) the effectiveness of the Company&#146;s disclosure controls and procedures. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Disclosure Committee will ensure effective procedures and protocols are in place at the Company such that
all the Company&#146;s SEC filings and material press releases are vetted for accuracy, integrity, and completeness, and for reviewing with management its ongoing compliance with these protocols and procedures. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The approval of the Disclosure Committee shall be required prior to any earnings releases or SEC filings, and
such approval shall not be granted without first fully considering the Company&#146;s abilities to meet any applicable goals or targets and determining that any authorized corporate public statement is true and accurate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Disclosure Committee shall hold regular meetings prior to the preparation and filing of the Company&#146;s
annual and quarterly reports with the SEC, and ad hoc meetings from time to time. Other personnel of the Company, or representatives of its outside advisors, may be invited to attend Disclosure Committee meetings as deemed necessary or appropriate
by the Disclosure Committee in performing its duties and responsibilities. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>The Science and Technology Committee
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BioMarin shall amend the Charter for its Board-level Science and Technology Committee (the &#147;Science
Committee&#148;), and post the new Charter on the Investor Relations portion of its website and include a link to this charter in each Proxy Statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Science Committee shall be comprised solely of Independent Directors (as defined in the existing charter)
and persons who have no financial or other material interest in any matter to be reviewed. At least two members of the Science Committee must be a scientist (Ph.D. level) or medical doctor, with relevant work and/or academic research experience.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Science Committee&#146;s responsibilities shall include evaluating the impacts of developments relating to
preclinical studies and near-clinical phase programs on the Company&#146;s collaborations and drug development plans, including but not limited to BioMarin&#146;s relationships with any collaborating entities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Science Committee, from a scientific and technical perspective, shall review, evaluate, and advise the
Board and management regarding the long-term strategic goals and objectives and the quality and direction of the Company&#146;s research and development (&#147;R&amp;D&#148;) programs, and regularly review the Company&#146;s R&amp;D pipeline.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Science Committee shall identify and discuss new and emerging trends in health care, pharmaceutical
science, technology, manufacturing, and regulation to assist the Company in making well- informed choices in the investment of its R&amp;D resources, and recommend to the Board and management emerging technologies for potentially building the
Company&#146;s technological assets and capabilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Science Committee shall assist management in identifying world- class experts, including potential members
for scientific advisory boards, to provide strategic scientific and clinical advice regarding the Company&#146;s programs and, in coordination with the Company&#146;s management, engage with the Company&#146;s scientific advisory boards and other
advisors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Science Committee shall ensure that the Audit Committee and the Board are promptly made aware when any
issues arising out of a clinical trial, including those pertaining to clinical trial data and protocols, are sufficiently material to trigger a disclosure obligation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Science Committee shall have access to all communications to the Company from the FDA, or from the FDA to
the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Science Committee shall meet from time to time as it deems necessary to perform its responsibilities, but
in no event less than twice annually, and shall report regularly, but in no event less than twice annually, to the Board. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Science Committee may from time to time request any officer(s), employee(s) or advisor(s) of the Company to
meet with the Science Committee or any advisor(s) engaged by the Science Committee; </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>The Public Data Disclosures to
Stockholders </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If management and/or the Board chooses to publicly release interim product candidate results, the Company will
do so in a manner that is not false or misleading. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At least a subset of the Disclosure Committee shall review any disclosure releasing new clinical trial data
before it disseminated to investors; </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Improvements to the Audit Committee </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BioMarin shall adopt a resolution to amend its Audit Committee Charter, and post the amended Charter on the
Investor Relations section of the Company&#146;s website. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amended Charter shall provide that the Audit Committee shall plan to meet at least six (6)&nbsp;times
annually and in separate executive sessions with the Company&#146;s management, independent auditor, and Chief Compliance Officer in carrying out its duties. The Chief Financial Officer will not be present at such meetings. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Audit Committee shall, in conjunction with BioMarin&#146;s independent outside auditor, annually review
staffing of the Company&#146;s internal audit function to ensure that necessary staffing levels of the internal audit function are fulfilled and maintained. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Audit Committee shall meet with the Disclosure Committee, or its designee, at least four times annually to
discuss the Company&#146;s R&amp;D, production, and/or marketing goals as it relates to material press releases, SEC Form <FONT STYLE="white-space:nowrap">10-Qs,</FONT> and Form <FONT STYLE="white-space:nowrap">10-Ks</FONT> to align on processes and
procedures to facilitate accurate public disclosures. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Limited Director and Committee Engagements </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">u)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BioMarin shall limit director and committee engagements outside the Company to help ensure that each director
fulfills his or her fiduciary oversight duties by devoting sufficient attention to BioMarin&#146;s business and operations. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Expansion of the Duties and Responsibilities of the General Counsel </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The duties and responsibilities of the Company&#146;s General Counsel shall be expanded to include liaising
between management, the Board, and the Audit Committee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">w)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In conjunction with the CCO, the General Counsel shall: (i)&nbsp;be primarily responsible for identifying and
initiating investigations into material misconduct and noncompliance with applicable laws and regulations; (ii)&nbsp;if the General Counsel determines that there has been <FONT STYLE="white-space:nowrap">non-compliance</FONT> with applicable laws
and regulations, report those issues to the Disclosure Committee and the Audit Committee, within three days of identification of these issues; and (iii)&nbsp;make recommendations for further evaluation and/or remedial action within deadlines agreed
to by the Disclosure and Audit Committees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As part of the Disclosure Committee, review BioMarin&#146;s draft quarterly and annual reports, filed with the
SEC on Forms <FONT STYLE="white-space:nowrap">10-K</FONT> and <FONT STYLE="white-space:nowrap">10-Q,</FONT> and related materials prior to their publication to ensure (i)&nbsp;the accuracy, completeness, and timeliness of disclosures relating to
compliance with applicable laws and regulations; and (ii)&nbsp;accurate reporting of any material issues that may merit disclosure to other BioMarin constituencies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">y)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As part of the Disclosure Committee, review BioMarin&#146;s press releases and related materials prior to their
publication to ensure the accuracy, completeness, and timeliness of disclosures relating to BioMarin&#146;s compliance with applicable laws and regulations, and reporting any material issues that may merit disclosure to other BioMarin
constituencies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">z)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Working with the Audit Committee as a part of the Disclosure Committee&#146;s subcommittee to evaluate the
adequacy of BioMarin&#146;s internal controls over compliance and develop proposals for improving these controls. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Internal Controls and Compliance Functions </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">aa)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By no later than December&nbsp;31, 2024. the Board shall work with an independent consultant to strengthen its
internal audit and control functions, including, but not limited to, the accuracy of public disclosures. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">bb)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The consultant shall prepare a written report with recommended changes, if any, to the Audit Committee. This
consultant shall meet with the Board and a member of senior management to present the written report in advance of BioMarin&#146;s finalization of its annual Form <FONT STYLE="white-space:nowrap">10-K</FONT> report for the year end December&nbsp;31,
2024. The Board shall consider implementation of each recommendation contained in the report, and such consideration shall be recorded in the meeting minutes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">cc)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BioMarin&#146;s CFO shall not have been employed by any of BioMarin&#146;s outside auditor firms during the
prior two (2)&nbsp;years or, if involved in the auditor firm&#146;s audit of BioMarin, during the prior five (5)&nbsp;years. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Insider Trading Policy And Controls </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">dd)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent not already required, the Company&#146;s Insider Trading Policy shall be amended, and the amended
policy posted on the Company website. The amended policy shall provide that when Company insiders elect to enter into <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans (&#147;Trading Plans&#148;), the Trading Plans shall prohibit the
commencement of trading until ninety days (90)&nbsp;following a Trading Plan&#146;s adoption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ee)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The adoption of a Trading Plan, and the aggregate number of shares involved, shall be publicly disclosed for
Section&nbsp;16 officers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ff)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Trading Plans shall only be adopted during &#147;open window&#148; periods. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">gg)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Trading Plans shall be approved by the Company&#146;s General Counsel or designee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Director Education </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">hh)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BioMarin shall require that every three years, each member of the Board shall receive director training and
that training may be conducted either at an outside entity or internally by the Company&#146;s General Counsel or outside counsel. Any such programs or training may concern, for example, compliance with laws and regulations, disclosures to
stockholders, and fiduciary duties in the context of a regulated public company, including compliance with GAAP, the Sarbanes- Oxley Act, corporate governance, assessment of risk, compliance auditing, and reporting requirements for publicly-traded
corporations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All new Board members shall receive such training within six (6)&nbsp;months of election or appointment to the
Board. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Employee Training </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">jj)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall provide all new hires and appropriate employee populations with training on expectations with
respect to integrity and compliance and the Code of Conduct. The Company shall require the appropriate employee populations to attest on an annual basis that they have read, understand, and will comply with the Code of Conduct.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Whistleblower Policy </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">kk)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall adopt and implement a written policy (the &#147;Whistleblower Policy&#148;) to protect
employees, contractors, vendors and other individuals from retaliation for reporting misconduct, <FONT STYLE="white-space:nowrap">non-</FONT> compliance with applicable laws and regulations or violations of the Company&#146;s Corporate Governance
Principles, Global Code of Conduct and Business Ethics, Corporate Compliance and Ethics Program, and Environmental, Social and Governance (ESG) Practices. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ll)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Whistleblower Policy will adequately notify employees of the following: (i)&nbsp;complaints may be directed
to an employee&#146;s manager, any member of Human Resources, that employee&#146;s designated officer, or via a whistleblower phone number (the &#147;Reporting Hotline&#148;); (ii) reports made through the Reporting Hotline made be made anonymously
(unless prohibited by local law); (iii) information gathered during investigations into reports will be kept confidential to the extent possible; and (iv)&nbsp;BioMarin strictly prohibits retaliation against any individual who raises complaints in
good faith. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">mm)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall post information regarding the Reporting Hotline phone number on the Company website and make
clear that it is available to assist on matters pertaining to a potential violation of the Code of Conduct. The Reporting Hotline shall be confidential, and reports made to the Reporting Hotline relating to accounting, auditing, or embezzlement
matters shall be directed to the Chairperson of the Audit Committee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. Defendants shall pay for, and administer,
notice of any settlement in a form and manner mutually acceptable to the parties. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WHAT ARE THE PARTIES&#146; REASONS FOR THE SETTLEMENT?
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. The Settlement set forth in the Stipulation reflects the results of the Parties&#146; negotiations and the terms of the Stipulation,
and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">agreement-in-principle</FONT></FONT> was reached only after <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations, with the assistance of&#151;and following a
mediator&#146;s proposal from&#151;Ms.&nbsp;Yoshida as mediator, among the Parties, all of which were represented by counsel with extensive experience and expertise in stockholder derivative litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27. Plaintiffs believe that the Released Claims had merit when filed and continue to have merit, and Plaintiffs are settling the Released
Claims because Plaintiffs believe that the Settlement will provide substantial value to the Company and its stockholders. Plaintiffs have concluded that the Settlement is fair, reasonable, and in the best interests of the Company and its
stockholders, and that it is reasonable to pursue the Settlement based on the terms and procedures outlined in the Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.
Defendants have denied, and continue to deny, that they have committed or threatened to commit any violations of law, breaches of duty, breaches of contract, or other wrongdoing toward the Company, Plaintiffs, or anyone else concerning any of the
claims, allegations, or requests for relief set forth in the complaints filed in these Derivative Actions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29. If the Settlement is approved, the Court will enter an order approving the Settlement in
accordance with the Stipulation, at which time the Derivative Actions will be dismissed with prejudice on the merits. The first date by which such order is finally affirmed on appeal or is no longer subject to appeal, and the time for any petition
for <FONT STYLE="white-space:nowrap">re-argument,</FONT> appeal or review, by leave, writ of certiorari, or otherwise, has expired, constitutes &#147;Final Approval.&#148; Upon receipt of Final Approval, and subject to the conditions set forth in
the Stipulation, the following releases will occur: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Released Parties shall be deemed to have, and by operation of the Order and Final
Judgment approving the Settlement shall have, completely discharged, dismissed with prejudice on the merits, released and settled, to the fullest extent permitted by law, the Released Claims against the Released Parties (as defined below) and shall
be forever barred and enjoined from commencing, instituting, prosecuting, or continuing to prosecute any of the Released Claims against any of the Released Parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The obligations incurred pursuant to the Stipulation shall be in full and final disposition of the Derivative Actions and each of the Released
Claims. It is the intention of the Parties that the Settlement eliminate all further risk and liability relating to the Released Claims, and that the Settlement shall be a final and complete resolution of all claims asserted or which could be or
could have been asserted with respect to the Released Claims against any of the Released Parties, including without limitation any claims for contribution in accordance with <I>10 Del. C</I>. &#167; 6304 and any similar laws or statutes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Released Claims&#148; means Plaintiffs&#146; Released Claims and Defendants&#146; Released Claims; provided, however, for the avoidance
of doubt, that Released Claims shall not include any claims relating to the enforcement of this Stipulation or Settlement or any claims by BioMarin or the Individual Defendants for insurance coverage or any claims by the Individual Defendants for
indemnification or advancement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Released Defendant Parties&#148; means all Defendants in the Derivative Actions, and any and all of
their and BioMarin&#146;s respective current or former agents, parents, controlling persons, general or limited partners, members, managers, managing members, direct or indirect equity holders, subsidiaries, affiliates, employees, officers,
directors, predecessors, successors, attorneys, heirs, assigns, insurers, reinsurers, consultants, and other representatives, servants and related persons, in their capacities as such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Plaintiffs&#146; Released Claims&#148; means all claims and causes of action of every
nature and description, whether known or unknown, whether arising under federal, state, common or foreign law, including Unknown Claims, that arise out of or relate in any way to Released Plaintiff Parties&#146; (as defined below) institution,
prosecution, or settlement of the Derivative Actions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Released Plaintiff Parties&#148; means Plaintiffs and Plaintiffs&#146; Counsel
and each of their respective agents, assigns, and related persons. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Released Party&#148; or &#147;Released Parties&#148; means each
and all of the Released Plaintiff Parties and the Released Defendant Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Released Parties&#148; means the Released Plaintiff
Parties and the Released Defendant Parties, individually or collectively as the context may require. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Settlement is intended to
extinguish all of the Released Claims by the Releasing Parties as against the Released Parties and, consistent with such intention, upon Final Approval of the Settlement, the Releasing Parties shall waive and relinquish, to the fullest extent
permitted by law, the provisions, rights, and benefits of any state, federal, or foreign law or principle of common law, which may have the effect of limiting the Released Claims. This shall include a waiver of any rights pursuant to California
Civil Code &#167; 1542 (and equivalent, comparable, or analogous provisions of the laws of the United States or any state or territory thereof, or of the common law), which provides: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE
TIME OF EXECUTING THE RELEASE, AND THAT IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR THE RELEASED PARTY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30. If the Settlement is approved and Final Approval occurs, since the Company will have released the Released Claims described above against
the Released Parties, no Company stockholder will be able to bring another action asserting those claims against those persons on behalf of the Company or individually. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31. Pending final determination of whether the Settlement should be approved, all
proceedings in the Derivative Actions, other than such proceedings as may be necessary to carry out the terms and conditions of the Settlement and determine a fee award, have been stayed and suspended. Subject to an Order of the Court, until the
earlier of Final Approval (defined below) or an order of the Court substantially denying or declining to approve the Settlement in accordance with the Stipulation, the Released Parties, or any individual, are barred and enjoined to the maximum
extent permitted under law from commencing, prosecuting, instigating, or in any way participating in the commencement or prosecution of any action asserting any of the Released Claims, either directly, representatively, derivatively or in any other
capacity, against any of the Released Parties. The Parties agree to use their best efforts to prevent, stay, seek dismissal of, or oppose entry of any interim or final relief in favor of any of the Released Parties in any other litigation against
any of the Released Parties or their affiliates that challenges the Settlement or brings claims, the release of which are contemplated by the Stipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32. &#147;Final Approval&#148; means the later of (a)&nbsp;the expiration of the time for the filing or noticing of an appeal or motion for
reargument or rehearing from the Court&#146;s Order and Final Judgment approving the Settlement; (b)&nbsp;the date of final affirmance of the Court&#146;s Order and Final Judgment on any appeal or reargument or rehearing; or (c)&nbsp;the final
dismissal of any appeal. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HOW WILL THE ATTORNEYS BE PAID? </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33. Concurrent with seeking final approval of the Settlement, Plaintiffs&#146; Counsel intends to petition the Court for an award of
attorneys&#146; fees and expenses not to exceed $1,250,000. Plaintiffs&#146; Counsel also intends to seek a Service Award of up to $2,000.00 to be paid to each Plaintiff for their reasonable efforts in prosecuting the Derivative Actions. Any such
Service Award shall be paid out of the Fee Award granted to Plaintiffs&#146; Counsel. Defendants agree not to object or oppose the requested Fee Award. Plaintiffs&#146; Counsel will make this petition not less than thirty (30)&nbsp;calendar days
prior to the Settlement Hearing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">34. Any award to Plaintiffs&#146; Counsel for fees and expenses and any service fee to Plaintiffs shall
be determined by the Court. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WHEN AND WHERE WILL THE SETTLEMENT HEARING BE HELD? DO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I HAVE THE RIGHT TO APPEAER AT THE SETTLEMENT HEARING? </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35. The Court will consider the Settlement and all matters related to the Settlement at the Settlement Hearing. The Settlement Hearing will be
held before The Honorable Nathan A. Cook on July&nbsp;23, 2024, at 11:00 a.m., Court of Chancery of the State of Delaware, Leonard L. Williams Justice Center, 500 North King Street, Wilmington, DE 19801, or as may be undertaken via a remote
proceeding such as Zoom or by telephone. Any current stockholder who objects to the Settlement, the application for attorneys&#146; fees and expenses by Plaintiffs&#146; Counsel, or Plaintiffs&#146; application for Service Awards, or who otherwise
wishes to be heard, may appear in person or through his, her, or its attorney at the Settlement Hearing and present any evidence or argument that may be proper and relevant; provided, however, that no such person shall be heard or entitled to
contest the approval of the terms and conditions of the Settlement, or, if approved, the Order and Final Judgment to be entered thereon, or the allowance of fees and expenses to Plaintiffs&#146; Counsel, or otherwise be heard with respect to the
matters considered at the Settlement Hearing unless, no later than twenty (20)&nbsp;calendar days before the Settlement Hearing, such person files with the Register in Chancery, Court of Chancery of the State of Delaware, Leonard L. Williams Justice
Center, 500 North King Street, Wilmington, DE 19801, the following: (a)&nbsp;proof of ownership of the Company&#146;s stock as of April&nbsp;9, 2024, and continuously to the present; (b)&nbsp;a written and signed notice of the Objector&#146;s
intention to appear, which states the name, address and telephone number of the Objector and, if represented, his, her, or its counsel; (c)&nbsp;a detailed statement of the objections to any matter before the Court; and (d)&nbsp;a detailed statement
of all of the grounds thereon and the reasons for the Objector&#146;s desire to appear and to be heard, as well as all documents or writings which the Objector desires the Court to consider. Any such filings with the Court must also be served upon
each of the following counsel (by <FONT STYLE="white-space:nowrap">e-service,</FONT> hand, or overnight mail) such that they are received no later than twenty (20)&nbsp;calendar days prior to the Settlement Hearing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Timothy J. MacFall </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">RIGRODSKY
LAW, P.A. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">300 Delaware Avenue, Suite 210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Wilmington, DE 19801 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(302) <FONT
STYLE="white-space:nowrap">295-5310</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Counsel for Plaintiff Elaine Wang</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Rusty E. Glenn </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">SHUMAN,
GLENN&nbsp;&amp; STECKER </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">600 17th Street, Suite 2800 South </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Denver, CO 80202 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(303) <FONT
STYLE="white-space:nowrap">861-4531</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Counsel for Plaintiff Bill Tsantes</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">D. McKinley Measley </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">MORRIS,
NICHOLS, ARSHT TUNNELL LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1201 N. Market Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">P.O. Box 1347 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Wilmington, DE
19899-1347 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(302) <FONT STYLE="white-space:nowrap">658-9200</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Brett De Jarnette </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">COOLEY LLP
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3175 Hanover Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Palo
Alto, CA 94304-1130 (650) <FONT STYLE="white-space:nowrap">849-7005</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Attorneys for Defendants Bienaim&eacute;, Anderson, Dere,
Heron, Hombach, Lawlis, Meier, Pyott, Slamon, Grey, Alles, Fuchs, and Nominal Defendant BioMarin Pharmaceutical Inc.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">36. Unless the
Court otherwise directs, any person who fails to object in the manner prescribed above shall be deemed to have waived his, her, or its right to object and shall be forever barred from raising any objection to the Settlement or the application by
Plaintiffs&#146; Counsel for an award of attorneys&#146; fees and expenses, or any other matter related to the Settlement, in the Action or in any other action or proceeding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CAN I SEE THE COURT FILE? WHOM SHOULD I CONTACT IF I HAVE QUESTIONS? </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Notice does not purport to be a comprehensive description of the Derivative Actions, the allegations related thereto, the terms of the Settlement, or the
Settlement Hearing. For a more detailed statement of the matters involved in the Derivative Actions, you may inspect the pleadings, the Stipulation, the Orders entered by the Court, and other papers filed in the Derivative Actions at the Office of
the Register in Chancery in the Court of Chancery of the State of Delaware, Leonard L. Williams Justice Center, 500 North King Street, Wilmington, DE 19801, during regular business hours of each business day. If you have questions regarding the
Settlement, you may write or call Plaintiff&#146;s counsel: Timothy J. MacFall, RIGRODSKY LAW, P.A., 300 Delaware Avenue, Suite 210, Wilmington, DE 19801, (302) <FONT STYLE="white-space:nowrap">295-5310;</FONT> Rusty E. Glenn, SHUMAN,
GLENN&nbsp;&amp; STECKER, 600 17th Street, Suite 2800 South Denver, CO 80202, (303) <FONT STYLE="white-space:nowrap">861-3003;</FONT> Brett D. Stecker, SHUMAN, GLENN&nbsp;&amp; STECKER, 326 W. Lancaster Avenue, Ardmore, PA 19003, (303) <FONT
STYLE="white-space:nowrap">861-3003;</FONT> Gustavo F. Bruckner, Samuel J. Adams, POMERANTZ LLP, 600 Third Avenue, New York, NY 10016, (212) <FONT STYLE="white-space:nowrap">661-1100.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DO NOT CALL OR WRITE THE COURT OR THE OFFICE OF THE REGISTER IN CHANCERY REGARDING THIS NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">37. Brokerage firms, banks, and other persons or entities who hold shares of the Company&#146;s common stock as record owners, but not as beneficial owners,
are directed to either (a)&nbsp;promptly request from the Company sufficient copies of this Notice to forward to all such beneficial owners and after receipt of the requested copies promptly forward such Notices to all such beneficial owners; or
(b)&nbsp;promptly provide a list of the names and addresses of all such beneficial owners to the Company, after which the Company will promptly send copies of the Notice to such beneficial owners. Copies of this Notice may be obtained by calling the
Company toll-free at 1 (833) 243-3003. A copy of the Stipulation can also be found on the Company&#146;s Investor Relations page at https://investors.biomarin.com/overview/default.aspx. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BY ORDER OF THE COURT:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> <U>&#8195;&#8195;</U>,
2024</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Register in Chancery</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Multi-Case Filing Detail:</B> The document above has and/or served into multiple cases, see the case
number and name. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction Details </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Court: </B>DE Court of Chancery Civil Action</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Document Type:</B> Exhibits</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transaction ID: </B>72616079</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Document Title: </B>Exhibit C to Stipulation of Compromise and
Settlement<B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Submitted Date</B><B></B><B>&nbsp;&amp; Time:</B>Mar 27 2024 12:01PM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Case Details </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Case Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Case Name</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">2023-0058-NAC</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elaine Wang vs. Jean-Jacques Bienaim&eacute;, et. al.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">2023-0569-NAC</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bill Tsantes v. Jean-Jacques Bienaim&eacute; et al</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bmrn-20240409.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 4/24/2024 12:04:53 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:bmrn="http://www.bmrn.com/20240409"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.bmrn.com/20240409"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20240409_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20240409_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>bmrn-20240409_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 4/24/2024 12:04:53 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>bmrn-20240409_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 4/24/2024 12:04:53 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="bmrn-20240409.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g797498g04g04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g797498g04g04.jpg
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M"  )! 8" P4* 0$!                     !   04!  $$ @$$ 04
M! $" P4&!P@ $1(3%!4A,2(6"1=!43(C)!$!                     /_:
M  P# 0 "$0,1 #\ ^_CT$]!/0!/IWD'R[D[D#TNB&EOY7N'$S-4YMC>DGJ*A
M@M>X,=7N!*L85_\ F_(^IDR_PU?0 VJ\FNN;DV:'GGCWIYJR;YLK[W4O=2@P
MND*=$+-;Q3)%.(YL43ON':CY(U]G?)6_U#>8MYY,I%8RE\8IF?1+)(-#!LJV
M>?Z7P-E2)B1HC#7AJQ43XJU9_FC4]G-7T&ED>2G5\A%$?T+@VL JB"+)5*JV
M-.4 :%)Y@6%_BN)1'K&QK9I/;X-5WR3W1%3T!QYQW_F'4 $.SF@BA7X*]XEP
MW]4;"C?I21I Y:QO%D9++\%9+\)/DB_V^W\^@-'H)Z">@GH.$LL<,<DTTC(H
M8F/EEED<C(XXXVJ]\CWN5&M8QJ*JJO\ ")Z"MSK/DCU#K>[LN*>+M+*4%1N%
M=T3K1<<#,X-62F"BVE7E[>:9U41,E><KYB/L9-!\?E$URI[^@Z7X?D/BSP?H
M_DB3";VS5\WQYQEMH+,PO3K/%3,#<\:N)G'6:SJ*IDC9D)?^3(V!CUCD1$_@
M-%\@O)WJ]%9OSM/[E4=<1XG=;I='DXBAP-ARCL71V<RW./O" X3U';4G?,^(
MH7V>H#VN54^#E] QW;++980GQ;III=2)S0S>DB=HN:8@V[2MCCR]B?F:[07#
M(_V[<B?KE:,\A&(JHR%LBM1RKZ!=NR>3^TXCKNP6N7N;[:<]XYQ3G>8IZ[1I
M%-'K._\ ==J4SG$9YTXH=D:*#4N"%D09'+\#?[D^;/0,!M*C@W1NB57";]&4
MW>]#@YM_:WW/!7@?KI,V;5U]P3-;,C?7RDI=%-:T<J.2=T/M\OC_  OH,&FZ
M1N/&!]?G^Z6<&DYW=W4XV=ZE71E/%KR+:U=*)6:%LBD3 N'$G5?FY?I>D3OK
M=_1GH'D /#M A+*O(B+!.'B*$*A=\HB!YV))%+&[^/=CV.14]!E^@GH*T?+7
MH6T[#O0?$/CMZ?G#;<-EMU'<@)>U3J:@&? <32TFOKQ2Z@.T?7M>\J(A$]V?
M&)?97JGH%VZWY1<^\8-]SWQVJLM8NY4@%=K]Y/5X2]U6K\A^?/HY)M-TKF5I
MSYGTVLO,]57!CZD1S%G_  S%5(_H5JJ#7>/<%?PO!ZO':735NJ\>=D=%I/&?
M.W UB;T*/GO21);8[E]WF; 52)L[G[:R<'4?>Q7M )8.1\4A3T'1E)>IJV?+
M<ZYWCO';)@"_7GH]=&^QT\F#RYXDX_W@@O.(SE>M828L L[O_@)5C6-]E>OH
M%+XSYNA=8Z9)QZC[!UX(H)VA+3HFBQV/K\WKZG(G  G&4M<21(:XFYL()F-A
M1$=\)7N3V1K?8'/VM?T-!*[/[^BYEY$53&4&_%&L:^/$[ \O+RG6>>L01YGO
MH)-$%HU$:!_[_85(UD_A[F^@T_FF%H-'WC_EGE-X5G[(;E;.4WW,M6,^NU.2
MBNML1J;SJLDATDQMQH[F,#\%S'M]FJV.1SG(GMZ &>)'<*JHYQG/'/M>8Z3K
M[S:+UO23<[+Q]MM[S,\DL>O;'_&NB]3NW21PX[$VM6Z$>E82K2IHQ7S,8C6-
M5 ;/G>VN^,]%BY-K[0FUP5N"EKSC5SO&(&-I#S615T;S(I%; VG;*P5[?=SI
M6/BF7V1R^@>7T C[QTQO'N1;SHWXA)\^9H2B:\,026PG(M2/B'4Q-!'5""VN
MLB(OE''[O<SW]OY]!4K7;YWCAXC7/5-?N1>"]L\@[E=^FY.Y'LMG09%+$^*W
M;8]:RL4]Y89;*6,TTHUH>B0(.'*V5(OLC5/0&O,6A6GQ&#ZKUW@^1RN[H[T&
MXX5E,KMJ_8X?3]J*H[%M7T+C^KRTK"Z+FVSHS4;-$6D,!+)HFEP?9&JN!MN2
M9^NKM<I73MO4Z+OAU&-?6&:<36P+E*NRE,A@6BI6.GG$>X1S0S9H)GC$2#(]
MK&^_R<!EL\G#+<OLXQQ2*PVILJRXKVCI,;=_MGMB<-(4Z2-@X#&.5SU3W=_'
M_;W]!\P^9H".7_[!^ST,EAS9<W0=*%R''^>VVMG#T^#R:I4VGXT6 KQ9C+L[
M2O/-<"7.2B%#^R.:JQJOH/J#7'TQUM77,D3WQ@U'ZP>ME;'-5_A3N9,L?XLB
M/8LL<T2*JN151/9/0"GL^3R]C99.R!N@<+U0 AP7.-?)\8OSK66)5@Q5M\%_
M*N*&Z^E/R!D1[F11J^/XN_\ (%JLMOI<[6==ZOSKCD>V[ML"L?ROI_.+:^JL
MS4MO*)MOF<IK-+K+-SOT?/AP+)Q!4<3)7_B3LDB:KY?Y#'7%]XV7 OT74UQO
M_,U"&G0\,+25(V8I1'@QE#VW):*DG(FOC<_15$2"PV2HUQ22CS2-:J(GH&J\
M9^HA]9Y'G-$/+,\L2%M-9QER2R'Q& 11Q^]@L\4,K3)HE:][5:BM<Y47^47T
M"H?[ G6&VT/CMPT58R*_>;]UW=5D<)TQA#,ZX.&L(?&(?6QE5 A5F]Q8[I5=
M(SV<QCG,1/0>YU#.=5DM6]7XKU/-\[PM(HG&>BX[J&93I.&Z)DZ&W3."7]8-
M1GLNLMJ:BXL3*U6$L?"="Y?O8UGP>H964&IL9MIJJBKZR/G/C7EJ?G_/(QG)
M"XK9W*2R;..L'".;#&VEJ$>R2LD'=]$(\4T2_!47T  Z-><]I1?)3L_<*"XU
M*9KOUIF\2-3,)!UDP%;G,B!E\CG-!3F5]D%6V)SB)R&_8^-%F5SF>WH,3C=%
MTG0]0QP^VTW0>10= RE[JH./%]9BU%8!5B7F?KZ8AOYE8-9!6,@A\\$XD1$S
M63HB(]51?0.\/Q/QY'U5KRLGD&50W0TC-V9K3&@$:W06%?9Q@_LGZ!TS]K%8
MUDY'RA*_)C9 CW1PJUJJWT "6MZKS;I-ES7)]2U&DR=MS^PTV# ()#M;!#':
MBHHJD6KOYV(V&$:2V=%.^7[F^S4>J_V_R&GW^,N\GVKG]_T0V36=!RO1N:U]
M1TMUC<F5@Q'3L]?56AR@67>X:HK"U;0Q3,-2![OQ7JJ_6]WMZ!A.F UT?2L)
MM2 9 \[UW]AQ[K-68\1 ))VCVE?D3;)A#7?)\=HV46%8FK*3/^(SW1D:^@0C
MF_,-1XH]NB[1V/:!4N=U?;B.:\_K^GZ;4=A\D=GFSP6YBA#R'ZM\&8S5#LKV
M5;D\$4%&U-4$Q995<K_8'3X6&9R_RQ[KRZ.>P3*Z>$'H65K)I(1:P"*\8ZQ/
M6M$?)-,?[6ZGQ.F8K?@C$:YO]%] %^P6DVE_V>\2R$H:D5^3Y[!H73*V!BP%
MD&V)H_PDLIV0D-20)KTBKHUL&*U\DKD&:YK@;*S\-N%)V&?O\P>P'T,!DFH.
MRP^\TX_+K'4"CK\-A9<Z;9-S!6AA;$C_ +G1)&^5J2O8Z1/GZ"HWI'D/9\.Y
M]CNABW_-\A9'6>YZ7I-9U%]V1AC%ZIN3L75:RHM8:H4NYO.69G#ES/H&*XB8
M*Q:R.1\;7+Z!B;DJ676VY]IRO4=HS.BV^%[1B*O.E5V)F2^W?/J&"6UL!KZ>
M%[!1C*1SH %19(W2.27^(T]PY=#=T.T\DLC8:WG^9XY7YKF^2M J_6=5Q4=[
M/6U_4!;.=E'>QS3T %;!,$_\Z.:>,HDMPZ(GU.5?0>KA?]@OCYT,NF[57=%Y
MO6;#1V4/'ESA4\Q]@^*OZ#HPADJ2(IUG( -DSY$TSVPHUC)6O_N:C54#C3"W
M$5WS/18>"OWXE()I\:8=RL^FEL<?(=J1-801=PW1 </^-6,=?"+^*.KW_=*U
M6(K7)[ />O[2V,L\1"5@=WB+H_H,G=KBIT0:V<U7!S(:*MMRPG OG@LA;6DM
M%5@+)$6)[%?$CW)\5 6Z;M)7D/5=?NLK6;$?,<KT=W>_Y61(;D$%W&8WE(-0
MXJE%=%)964576"DV1QP\,T:,F3ZVN<Y40+"F>+'$M)T)/(23-EC]GN:IC@>C
M":*\+N,N/:5(8)H^,&MB3*+.P&!0I'*X<".2=CG?8JJO\ ']E>$U/GWS.D$@
M)C_:<?66RLV"#2K;#PW%T @99A*,:/\ BR3,F5@_M-)[^_LK&+Z 7]H*SE1_
MLN\>BRG5<EP=SDV#\=T9)UI#$38V]4-82?>V.MS8,9)+(T*C<\DV16CHB,23
MT%G!]O1QD"TAMO5C6-Y&;#65I)X41UH@\:H:E>$0]93OQ6.]Y49'(C$_\D]O
M0?-UY)5#-#XSXFDKWGCU@@O;\Z+;[O,':[B-'T;EO0P.H<YL^F5=6VPO\9'=
M)7G#5=\+]?S@=,,L+(2&(@-9M_(BES/(N >3!73H]'2:"I<-LMUCJQ0<]L];
MEICCK&KR#S8HR): DLXX.G^IKI38*]6L]W?U!)/*+S^\%.C='O.'^1<&_NND
M9@7.II0-3SRU/RUMB1K+_*98L_+6-$#)S%B)&AL@SW/LST1C(VM1%3T +XD!
M_K<[)O#+'G'(J'*!;"*KFQF3!S!N7U652HUA\E!>A6MU)#:8JUVPA\\KWL>V
M-U:2P)J*0B.0+-N+:S$^/.'%RG,.;?J^I[K3V.=L:NI#D8=>SBWDYUYIJ4:^
MO#%K,QGA7QS$$%MC=70Q.=_>OP;Z!A[&U[QJ#M_<:.[KS:O*8NC;B;O*YT1^
MG@T5P8*1II0:LEQ"0S9X-L#7,E1SIU8LSF,:J)Z!,O'%+77<0ZCJ8(L>0634
MNRR- N](9I*32;S?MDN!(\W82PYR@;/(XC[%82ZSLY/X20:%T;/07[YN/Z,_
M1CK#(,Z"GK(WC31R0SCN:%"BQ3PS2SS13,5/9S7O>]'(J*Y5]U4*[KXNQN/]
ME%2 !+&\/-\>SS+!""8H(8)2['1V;AA/Q_NG)LIPT^Q82&Q,2%JN:Y55$] "
M/]H/[GG/:_#/R$;5@G97*=$-QFJ,+_7R15 UJP2_ISGPFPJHY<YE02-"8CG_
M (B3.2)J33M<@#GK(G//&_MS?(?L_;^:6UIGL-EL[XF\8KP-1J.PDUM]OR.B
M[FS6DC_<Z/\ S';0V* N(K!I(4#&]I)&1*YC )?8>9SONNF4&*T,F;F[S:TG
ME/XY3Y?4.QVL*ZKEJR([H0$EG^MGHOF: <H[F'J7!(MI#$^+XL54!),2S+>1
M> [%XQ]S+RD6,Z3C>:'\;MF;VCMS*76TVG(I>:TJ5N1+$CPEU7:\*=3"DA',
M+(L9Y%;]<2H@%;F'COXUV5LZ2QY3H@=W1DV=_P!/E'V_1VTB5&?SQC#K>TGA
MNYW4^OQ-]4R /C:J/=+]CX$3W:U0?OFGC/XV#8O"[R7)U5]9Z2BK1JFT*VTU
MW4VX6A2,RIK:Z;2S3SFTR0&0SB1N8]!W^SF?&1/EZ#1^O\0YKGN21ZKG])=9
M[3]C>)FZZCL-6ZIV,^KNB?R!VA6< ]E.=/,37-_91?\ LBG#B5\BJUB>P!KJ
M-ST+D?**KQZR6/W72=>?42R:#HU&%5'V>T\@-5$L0PDU%*X(MD,#YGV5N<]D
M( U8D<,BL>[X^@,/!<+T6JYYQCA/0Q:3.6D=G4Z[HW-Q*NA3.8K#XD=Q(%0(
M^F9=5TBZ.V9$6]ASX7N'148K)D17AZ=+TWR"W'3=%H.2!\UZKX][;;7.3FTO
M/NAV^;Z;C+<:RJ*2>VTV5W%:,.;_ ,?QA/ED@II%_('D5_UR(OOZ#=_%T0'I
MODIY'=YAN8;T&"X!Y[E#0+8B49M-GQY:F5I%<R*$%SB20)2(I5^R6-)7,_L]
MW(\&E\C^)TGD!R/4<XN&L9+81#65&:^/[$KM)2$QVF?/=$CX_O8)9CQO6-SD
M:Y/Z^@JTXMV6IS_*^@=CN\3S:M[=XYY>SQ'9M3M**8[LIF"RA-F)GL9G"X(?
MVY11=F1/7Q?<0*(5//"K7/8J.0";D)-7T3D_!^5>1][A^4>6>PCOO('QOSV8
MK:?+C\^FS9DYV7YQ-0BVUP3:$9',V(4-_*J,$-(F>D*NF';\06#MG*MQWZQ"
MT>=L1^>^0&-U=#LNP\+I<OA;;H@FTI1#J,#K/*='<6&9-OZN*2>5_P"DL''A
M7#4_('9')[,D 6^6_BYUGR0\82=5F-CO..>0-)C09NA:^O-O<M:#6P0Z4Y=Q
MT7+4#QIT2ZKJX<?7B_2CV#.BM!FK)#.V8!=XUT\6L\0*,6;8663\B?'L*CR&
MCSVAWU@EM@]-B+"I@R<^4K?MAJKZNWE-(3)42C,)6V@G@C@214]T!V9#>L\W
MP"^2G<PS;'I*108OE.1!'(ER7CWS_>Z8"H)T)M)_<RTWE@*0UYC6QS3I]<==
M$Y8T*=*&]\IH 1S;;L'5<KWO)[J]O[>; \QFT@XFHV8EF:(B5TM$)>VU_97"
MU]:A9;8DK(%_OB2-[T3T!2WI6/X'C]5INW8GIVWWG?EM,KU_8\) L==KN49"
MTK[.XSU&XFI@!U]?E@H(B7 S0B2S0$N='\Y&QQ.] '.6Y'F',:*_\LANMM[R
M=?T3<%P#H72B]!C.TUAA\G^/&XW3!V)M)S^YL,K5.B6.RFHA+B1!WM*E<OLY
M0LB\6./-XQR:JH2)K F\NBC-/?36I3##X["[F<<\&62!D(3/POO5JL'C9#]K
MGN3Y*Y7N!C_05X^1_)[7F/1X_*;FU7'8C$Q"UW>L)'71F0;_ #HL30JFY/;)
M',W\?+,EDGG;\%3V1)5_EBKZ!6>B8JM+P5_U#QQ?=]G\@?+O90T$'D;OIZHD
M7QOQ>6F;IJFIK;14 H<>)@! U=G*N)!H[V_6.8Q96J]4!N^A\NYQ)F^:VW?=
MZ'DNQ"'@9/D'6Q"JRMZW:/EJ0)X:2\0$5:O57Q<PY,EJ*'%(!\?G*.Z#Y*]H
M<IJ[N.4GATCN=9KNSHJ*:,#J7-KJFQFUNQ7@U 34MZ.V,?3WY)?S.<C)'%PQ
M1,8V-R2/7T":5?C5RV'R$9WR'QG\C:$RBCL(P,,-G968YVAJ;<T8 ZM#;/,$
M14(DGY-1%-&V.MC*?^%/#&LD2 TUSBN[=1)IK!_,LU2OCN #:/3]PT$<XF4&
MCFCA%=F.4Y3YP1:* (C[1TM'/D0R%T:OAC<QR!PVV]SW%>E1<YQL%'TCS0TN
M!JKS*#=,-+YSGNB8\*]CBT^1YGJ)0[#*UVD!9$04)4/F=-&LJ.FF_']W( :\
M;8^JW5'T'5=WT]T#PR*;:UEG:=YH0^?>0W(]7CMR+>XL/76#/LR&^H*D,V1U
M/;C-8CDD8B1R1.15 R\G6T\O>FP]@TN9*H>0\SM30^5 6GW"7.I.5$BM-!HJ
M0@6>G,J;R)_V#3CR(]\2-:[^JIZ"QY$1$1$1$1$1$1$]D1$_A$1$_A$1/0?O
MH.DD> P><0J*.<8J&4<B"5J/BF@F8Z.6*1B_P^.2-RHY%_A47T%>Q_C?J/'Z
MZW6EXI4 =!Y'NB&6&Q\>]-]1-4&88>$MQ;Y2(N&<*4 :M'>]E:Z-7/E^+6?+
MV]O0>99ZGG':.N\\[5B=#GX^M\>PG2<ED>2]+G?G8*K2[O\ %KA-"]'L?/6$
MOBHEB=)%"I$U3*_ZT17(U0&/C;XV=PR':(,EK]7KS<+R7@F"R1.]BO=924_0
M>E;K:;/J70]+SVO]YJ JOH2R@*:-"XGR0!*Z)%:J(U0Q.E=T\AJ3R&[90XC2
MV^B=D._>)V/R/,)JVN=36O.NJ41'_*\44@M8RW_)IP8IK5A_Y*J)(-\7)\'?
M%0TC*9'N71O&@T6YN[[<^2?%.V&ZK 6:6^L>3MCO'3LMJ77 ZT,P6IQU4_=Y
M@E Q%C208T>5DJN5T**T"QY5;?QMNK&"7R;_ $Y=@ H_^!\JRMT;;](H]SG[
M2&WSFQ6^R)*1<_TH#Y)09BOR/@+%*GRF1KW-]! .2]^\T-*,?WVLL>0^..>_
M5'X_FE3>UMM9=%>+9#$_#HHQPME^8+$.$Q89_DUKE>KF,?[_ &*%G^;S=#CZ
M*LS.8J0**@IA(P:NIK!HA @A8D]F1000M;&Q/^J_Q[JJJJ_ROH/;]!/03T$]
M CGDER3P^ZM<6-7T_<X? =0:  ^:_J^BYW$]$& @^V2L_90SV4)!]2YSE_L*
M@?'+&GP1?CZ &3^*_EC0 AN\?_-2&TRS(J[].#M*8>X5]3!5B->@=Q3%3ULL
MQ\HD+87,'B'AA>]Z-<Z3W0,DG&?[-2;HL(+I_CP"2^0B::WAK'OLX1)G"6 8
MSA%I9#9VA3L<&S[$8V8%RN5[)?BJAW,\5/*6S19.T>:#DRR'6Y5Q55%?/7"S
MYVU(A+/I#;AA^4)_$CM4:@),3A":N!$A20CY.50-_">6^(W/-#:LP>WP>XZ.
MZ[4326=AN\II=:_7C#-:;)95U<4Q!]7+ YJD2RC_ +%[$;]LCO;W4'8]!/03
$T'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g797498g41g41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g797498g41g41.jpg
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M" 8)  4"! H! P$!                     !   00"  8"  0%!0$!
M! (#!08!!P 1$A,4"!46(2,7"3$B,B0805%"0R5A&1$!
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M2EUI+B6UJX#TIQ@<$P27)1^ ,$S/2220,\E?GH0G.6B%_P ZL.*PUC^K'/\
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MCC:P_6[E;Y6P0:UCD0,P5,_(PJEH7FQ^.WEC*1\O.X!FKEKN]ZF3K?UXT.W
M62>+?LT]LB<MIYA<U.W<:!&&BMB[>EXD8O(\ (>4^\R"E3;SYK0C;;:!F.K
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MT\ T? 9P'YO,LD-.,/M-O,/-K:>9=0EQIUIQ.4.-N(7C*5H6C.<9QG'+.,\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140294136041760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOMARIN PHARMACEUTICAL INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001048477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  09,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0397820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">770 LINDARO STREET<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">SAN RAFAEL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">505-6700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMRN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4$L! A0#%     @ 8H&76&'%NG?N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 8H&76)E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !B@9=8!U<,D%8$  ".$   &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 8H&76)^@&_"Q @  X@P
M  T              ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !B
M@9=8EXJ[',     3 @  "P              @ %U#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " !B@9=8'#AEZC\!   \ @  #P              @ %>$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 8H&76"0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 8H&76&60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d797498d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:EntityRegistrantName -  d797498d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File>bmrn-20240409.xsd</File>
    <File>bmrn-20240409_lab.xml</File>
    <File>bmrn-20240409_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d797498d8k.htm">d797498d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d797498d8k.htm": {
   "nsprefix": "bmrn",
   "nsuri": "http://www.bmrn.com/20240409",
   "dts": {
    "schema": {
     "local": [
      "bmrn-20240409.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "bmrn-20240409_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmrn-20240409_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d797498d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-04-09_to_2024-04-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d797498d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-04-09_to_2024-04-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d797498d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.bmrn.com//20240409/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-24-107015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-107015-xbrl.zip
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MU8TP69WA]J8_Z\U5LVOLU]]02P,$%     @ 8H&76'A>%]UC!@  OT,  !4
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MGCT8RPM!6@FR4DC/^%ILP_*0KVXOQ1U7>LO\WHEL%TU_^X+>\Q]02P,$%
M  @ 8H&76)E<8PRU!   =2H  !4   !B;7)N+3(P,C0P-# Y7W!R92YX;6S5
MFN]OXC88Q]^?=/^#E[W9I LA@=Y65'IBM)W0:(N VZ:].9GD :PY=F2; O_]
M[( G J$CW6Z*JXH?B;^/OWX^CF.;W'S:I!2]@)"$LZX7-IH> A;SA+!%UUM)
M'\N8$ ])A5F"*6?0];8@O4^W[]_=?./[Z.YA\(1\M%0JDYT@6*_7C61.F.1T
MI71(V8AY&B#?M^7[T\_HUUUU'30&"E@"2K%4(-!/*T*33M2,6F$SC!K1H4P
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MH:H2NW,QZL[PG&_+LN4,RYX>=A(S]#Q0O+@4WI&HOK2.C%H\;6?P[+I;7[=
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MQHY/*KBQY/(C^O5KJ!SM=3.I%$94$0V#X<#M=KQC2W7%0>KU,KZNW<&T*;H
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MWTBUE51T?B:0>GGC_AX6*LP-+I9J6O2Q#MOMU9A*O?&^FBY4*);B5\<_\1;
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M2R^9TC,K<EXZX$3>\CH;N2@">19&ZBS 6\-3._("<3:UHYGMN(O$<VP_%JW
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M'2R!@Y_2LY*'!?0$&^9.<,GMA"XI/$T"&;8SQ<V>NEX$&SU:.!X@$3%:X.%
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M/TV=:TU>]>K$@C0+=$;V S4)@-/>C.TQ0$.X8P2@I87*4\ Z<BG0/^!0/K@
M?XM1'CL($4/\&W$9H,6).OBX4;0C5\2=.%)X==  $2P\ VUF-N>"R&0%%3S[
M^!H4D>JN2"E5E39RQ1?,=0THF;6',FR6I5+:;$=?/4FOCOAJA!%HQZ1L$V']
MG'I#4#'K:'>2L1/+2L3+-?,<;@#$O=/EGD&7V=(-^Q_SD'0E!V7]1"6!Q95R
MB4H5Q:FJ0?S IZQD..-#7ZJ?>(_4MJ7N@3PS3NA90_R/,I16] &N8,RZ[?-=
M,9P&^2"TK58*+:X550.F8B1YZJ\HU8D+-\C8=DS0@Q_^E+YE&LQ8C@*3%& <
M:L; *[$(!%[A1/BJ<FF&<3?(RLALK>$,,"+*<)>O@M7[X:%W!E3Y1>2R6AT[
MD<==/DU5%60V89\? 4@;O' 1T)^F&>V<OY(;55G2++52F5%@C:]O6,-G=6@0
MZO[29B.SUE!LP4@P&8^R1N"(+4B)!\SFN.[(X]0/GIR.QZ*TVHK*0$"B<>3-
M+AP4SIQ8P!Y?H=-P@CR-_I:2%IXN33GV)7Z(0'%C0<*2(PW]0C0*OT14>V"!
M!@D2/IP!H:U/-D9255BL7W!)"T/6XXQ38:^K,J7A>D2V^L^1ZWM#Z:**N5X&
M' G8??EA0682)B9/_GD14MJI-%>HE26WG4E'J!L:]A1]</61+L3[! V65 >,
MG:9ED G0Z4)(@XN39.B<TQMA"[S(6<S0X>;025%'),J8(50&(#G?@$@-:AQ2
MG2OY^TI*HR=N#8VU1N7&2V3&I[)+<S@LD!KFL/!/\A174@\G/>MF7KM'MX,0
M>WY[/7LV-,(,@S8MBQJ(2;L:U<6:\+;%\W 1&V@,,!K0G\1CY9()SI(('CQV
MH\P'8K!SJFM4A/%R7[#,8(3W1%#L769-BRN! 7GC(E8RA80J*[,\I"NV,-P4
MK80BK5)&5<M>+@:K[6Q V+U3Y+Y!D1S75I>&C;PZ(% Z8>YW5MH 2O*RH0\)
MO*A<4K6I.& !F5T0)J"[XM]C<EK-YRZ:3R*5US,F&0B3Y(12^C1U;?))C*-P
MEFJDRC&^,B3O.DGS_K6TWRB=-(UC^9AE\"-9ODK&]HW19J\J !6/!_T02P,*
M69:E<UXQ48JXU07+>/T(#[%IB\U-Z9.>B(V]-XT?JV((,O33\R91.(I_7&$A
MN8HXJ]:K*!3;KKNXQ*]$N]VHB/YT 2^IB"^^&P2RG*@]FW\$'=)U?B @)>]L
M.',QY/(_<-/94TG' [%F!=8J+UII87B>4P'P+\3>5PJ=DR4DA><Y3%XNF:!<
M_830$BE[@47_4CPK\6V*5R6R90?H-8C>A*NKT*IAXE5+8N(#6)GK(>#>ZRRH
MRL HQ+TWQTR/?BX.KR>*59#)K!&8K7AF8W#<=19&8^\= L^I;I!%0?A-:!8I
MS:>U9E_^:]!-W!&Y8;V2YP;="'VHS<T>\*WX]8J]+.8'7,LM!ZG+I=Q5'Q'3
MJ5!,F;[>^CP-+Y$]R+IV4L92>+Z22ABIELA#6^S8PZ@168''# C1BI>*/L"J
M:XYQTO+UB",S_%.JB?)9H!-J.I6#++::CEF5!564QN^@I0(=YDN/6_N(?*$=
MNGUT84ME[ 5CWMH&\][_4:X5'>4E>\62V#9H;LE$ "Q:V0B4[T"9*+6C@@MA
M9VMG&:Q5Q?ZF=984LP4!*>T<AE>!N2=\B34<(T:5&*!#11EA!@&)!>DM@3_L
M !ZG_\(GZ-]86)@>).'^WP(='UJ\8#RS-_)@Z&34'".LQ^*4F/<YF_OA%7%T
MY;^II,Z;=:)!6TRU&-$.&&()]"2,LU9_8RS0PD_8890&3RUI_I@PILT/JK*(
M7C#>/-@04(UMASUN@$LPS.JIX&1MMX@DC1K N#D%O^;)E$L(9PAO#2C3U@-U
M2;FT= J>2MSN%2Y($:PLD+O%49PJB%_76E8G$_'&$L+)^ )S-/14B_)V:5&N
MQY.KX">7];_>LO=4<S5M95F-9,D9E(4Y(O749B>#!:!<"IHME_!Y9(%=Z&@_
M"JU$YC#UB"%%Q! 18 "^BH0,0$'K!O5,R!A+ELY:0\?-K0N!,;4N%9U)/%S&
M7%)Z$$T'KAP+J>;-J%8Q>U'&8]=1@??*=I^KF8>."16ZPJ&"_7P.[$M$1IO^
M ?<?1]2SVE:];]VMO/AMS_HN1Q&=8XQ6\:GJ&U5&KF=L%2I?.<\E9&4S G4
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M,2WF D_%*AS8OX;:@]"3\78_O,SV *-K96\%2H,,[)G[**7W!M@E0F:?-^4
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M2G#OK=-WGJ_DUC$$5O.\44>5]WG$#$AI+/W]%RXFX)'KAK!EA96$5%?*J[P
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M?TQ,E^% %!)/(S5#?O+#W,#E>S[8S[B>^[>35G_0MH[:W6]63YJYGNW9EAE
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M;,C.6'F37;2:O/3O=_=K^SOO#__"9.8!ALO0F:!ZT7V0I(M4!T.=+PIGV+,
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M9M-?M$!8Z_87MFBZOGUI4ZM=W?9BPS!>&NV\B)" \A-E;'XZ5T5 N\?BS.H
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M$E5P#U0?PV<2+L>2$%^U$EDDFZ ;,$:0)V,"7?)GR@!*BWRG2)27G_ACC)'
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MA5O85L+Y$-YP.+<+1$])X#LX0_5DFM9ALB,F**?O1_6ENC1UWGTP4S',PV%
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M<;UV=7S:<<X/X<K._N<KO"L^3Y;F.FU<#Z[B^)#N?^9\_ HW.U4W^W+^^>3
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M&-(/;4$)K_;6QYIC+K89Q/V<@1%1SB:4]$Q5LX9]@GSGU'(XJ=N*V=("JN3
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MN*#[)7L9K7G&TU= _P82'['V";1<?Z.P[GFK9LGJPA+@_I[ZG%#/S:/4EN8
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M#@  9#<Y-S0Y.&0X:RYH=&U02P$"% ,4    " !B@9=8[FD/4U2;  !@Q0,
M$0              @ %4(P  9#<Y-S0Y.&1E>#DY,2YH=&U02P4&      4
,!0!  0  U[X

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d797498d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bmrn-20240409.xsd" xlink:type="simple"/>
    <context id="duration_2024-04-09_to_2024-04-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <startDate>2024-04-09</startDate>
            <endDate>2024-04-09</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2024-04-09_to_2024-04-09"
      id="Hidden_dei_EntityRegistrantName">BIOMARIN PHARMACEUTICAL INC</dei:EntityRegistrantName>
    <dei:EntityAddressStateOrProvince
      contextRef="duration_2024-04-09_to_2024-04-09"
      id="Hidden_dei_EntityAddressStateOrProvince">CA</dei:EntityAddressStateOrProvince>
    <dei:AmendmentFlag contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-274">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-04-09_to_2024-04-09"
      id="Hidden_dei_EntityCentralIndexKey">0001048477</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-285">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-286">2024-04-09</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-287">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-288">000-26727</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-289">68-0397820</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-290">770 LINDARO STREET</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-291">SAN RAFAEL</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-292">94901</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-293">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-294">505-6700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-295">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-296">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-297">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-298">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-299">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-300">BMRN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-301">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-04-09_to_2024-04-09" id="ixv-302">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
